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-hemoglobinopathies affect millions of people around the world. Research into 
treatments for these conditions has focused on methods to increase -globin expression, because 
increased levels of -globin ameliorate or reduce the severity of symptoms. As more and more 
studies have been done, a few proteins have emerged as having crucial roles in -globin 
repression and have been established as key genes to study. These are Krüppel-like factor 1 
(KLF1), B cell CLL/lymphoma 11A (BCL11A), and methyl binding domain 2 (MBD2). The 
roles of these proteins in the switch from fetal to adult hemoglobin and in repressing -globin 
expression have been investigated extensively. However, there are still questions that remain 
unanswered and knowledge gaps that need to be filled. This thesis focuses on the gaps for each 
of these three genes and presents approaches to answer these questions. Some of the questions 
discussed are how variants of KLF1 affect its function, if BCL11A regulates the -globin gene 
by binding at a distance or at its promoter, and how MBD2 binds at the -globin locus. One of 
the questions that is universal to the three genes is how they each interact with the -globin locus 
and if they each interact with each other in order to repress -globin expression. We propose 
knocking down different combinations of two of the three genes simultaneously to determine if 
the combinations have an additive or synergistic effect on increasing -globin expression, which 
could indicate whether the proteins are working in the same or different pathways. We provide 
evidence that dual knockdown of BCL11A and MBD2 in HUDEP-2 cells results in a 
significantly larger increase in -globin mRNA than single knockdown of either gene. Our 
evidence supports our rationale that further experiments on combinations of the KLF1, BCL11A, 
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and MBD2 gene knockdowns in HUDEP-2 cells and then further verification in CD34+ cells 




Chapter 1 – Background and Introduction 
 
 
1. Erythropoiesis  
 Erythropoiesis is the synthesis of erythrocytes (red blood cells). Red blood cells (RBCs) 
are essential for transporting oxygen and carbon dioxide throughout the body. The process of 
erythropoiesis is complex and consists of two phases, termed primitive and definitive 
erythropoiesis (1) (Figure 1). 
a. Primitive Erythropoiesis 
The first blood cells in mammals emerge in the yolk sac in regions called blood islands. 
This gives rise to the differentiation of erythroid progenitor colony forming cells (EryP-CFCs) 
from the mesoderm at the start of gastrulation (1) (2) (3) beginning in humans two weeks after 
conception (4). Primitive erythropoietic cells contain embryonic hemoglobin and begin to 
circulate throughout the body upon the start of cardiac contractions around the third week of 
development (5) (6). Despite the hemoglobin switch and the switch from primitive to definitive 
erythropoiesis, small numbers of EryPs are still present in the circulation up to five days after 
birth (7). Around the time that blood begins to circulate the primitive erythrocytes begin to 
mature into definitive erythroid precursors. The characteristics of this switch include the cells 
becoming smaller, enucleated, and beginning to accumulate hemoglobin (8) (9) (7). Studying 
this process has been done mainly in animal models because it is difficult to study in humans due 






b. Definitive Erythropoiesis 
Around the sixth week of human embryonic development there is a shift from primitive 
to definitive erythropoiesis (4). Definitive erythropoiesis occurs in the fetal liver until after birth 
when it switches to the bone marrow (10). This makes definitive erythropoiesis responsible for 
the creation of fetal hemoglobin (HbF) and adult hemoglobin (HbA). There are two stages 
definitive erythroid progenitors go through: burst-forming unit erythroid (BFU-E) and colony-
forming unit erythroid (CFU-E) (Figure 1). Human BFU-E progenitors are the earliest 
progenitors and require 14 days in culture to become mature colonies consisting of more than a 
thousand erythroid cells. The CFU-E progenitors arise from BFU-E progenitors, so they are 
more mature. Human CFU-E progenitors only require 7 days to form mature colonies consisting 
of 16-32 cells in culture (1). Next, the BFU-E progenitors differentiate into CFU-E progenitors 
(11). CFU-E progenitors are intermediate in size and divide quickly (12) (13). Their divisions 
result in mature cells that differentiate into proerythroblasts, basophilic erythroblasts, 
polychromatic erythroblasts, and finally orthochromatic erythroblasts (13) (Figure 1). The 
maturation into the final form, orthochromatic erythroblasts, is characterized by the 
accumulation of hemoglobin, a decrease in cell size, the condensation of chromatin in the 
nucleus, and a decrease in RNA content. This mature erythroid precursor then expels its 
condensed chromatin to become enucleate, forming reticulocytes – immature erythrocytes (1). 
The final step is for the reticulocytes to mature into RBCs. This process occurs through the loss 
of plasma membrane surface area, reducing cell volume, and the loss of all residual cytoplasmic 
organelles (mitochondria and ribosomes) – resulting in the biconcave disc of a RBC (14) (15). 




the bloodstream to balance the removal of senescent RBCs. This results in the transportation of 




2. Hemoglobin Switching 
a. Structure of the - and -globin genes 
In humans there are two families of globin genes, the - and -family globin genes. The 
-family globin genes are located on chromosome 16 in the order of  ζ2 (embryonic), ζ1 
(embryonic), α2 (fetal/adult) and α1 (fetal/adult) (17) (18) (Figure 2). The -family globin genes 
are located on chromosome 11 in the order of ε (embryonic) - Gγ - Aγ (fetal) - δ - β (adult), 
which happens to be in the order of their developmental expression (19) (17) (20) (Figure 2).  
Figure 1: Primitive and Definitive Erythropoietic Pathways 
The two pathways in humans that result in the generation of red blood cells. 
HSC – Hematopoietic Stem Cell, BFU-E – Burst-Forming Unit Erythroid, CFU-E – Colony Forming 
Unit-Erythroid, ProE – Proerythroblast, BasoE – Basophilic erythroblast, PolyE – Polychromatophilic 
erythroblast, OrthoE – Orthochromatic erythroblast, Retic – Reticulocyte, EryP-CFC – Erythroid 




The first hemoglobin to be expressed in humans is present during the first five weeks of 
fetal development and is the embryonic hemoglobin Gower 1 (21). It is comprised of two ζ- and 
two -globin chains, forming a 𝜁2ε2 tetramer. The second hemoglobin to be expressed is 
embryonic hemoglobin Gower 2, which is comprised of two - and two -globin chains to form 
the tetramer α2ε2. The third and final embryonic hemoglobin to be expressed is Portland 
hemoglobin. It has two ζ- and two -globin chains to form a 𝜁2γ2 tetramer (19) (17). These are 
the embryonic hemoglobins, so they are made in the yolk sac during primitive erythropoiesis 
(Figure 3). This is discussed in more detail in Chapter 1.1.a above.  
After expression of the embryonic hemoglobins during primitive erythropoiesis the site 
of erythropoiesis switches to the fetal liver where HbF is made (Figure 3). HbF has two - and 
two -globin chains to form the α2γ2 tetramer. The formation of HbF replaces the embryonic 
hemoglobins as the predominant form of hemoglobin circulating in the blood for the remainder 
of fetal development (19) (17) (18) (20). Towards the end of human fetal development 
production of HbA begins, leading to a gradual decline in the amount of HbF as the levels of 
HbA increases (22) (23) (Figure 3). HbA is comprised of two - and two -globin chains to form 
a α2β2 tetramer. At birth there is a switch where the expression of HbF is almost entirely 
silenced, leading to HbA being the predominant form of hemoglobin expressed (Figure 3). This 
switch is discussed more in the next section (Chapter 1.2.b). This results in the composition of 
human blood to be about 97% HbA, 2% HbA2 (α2δ2), and 1% HbF by around 6 months of age 






b. Hemoglobin Switching 
Hemoglobin switching is the term for the developmental changes in hemoglobin 
expression that are described above (Figure 3). The term covers the two switches observed in 
humans; the first switch is from embryonic hemoglobin to HbF and the second switch is from 
HbF to HbA (24). Understanding how the HbF to HbA switch is controlled is a huge focus for 
studies aiming to develop treatments for individuals with -hemoglobinopathies. Studies of 
chromosomal looping, gene interactions, protein interactions, and genetic regulation involved in 
this switch (all to be discussed later in this thesis) are crucial for understanding how the HbF to 
HbA switch occurs. If these aspects to hemoglobin switching are understood, then they can be 
harnessed to reactivate the expression of HbF as a treatment for -hemoglobinopathies.  
c. -globin Locus Control Region (LCR) 
The locus control region (LCR) is a DNA regulatory element located in cis to the human 
-globin locus at a distance 50 kb upstream of the -globin gene. It is required for the -globin 
genes to be normally expressed during all stages of development (26) (27) (28) (29) (30) (31). 
The LCR controls the expression of the genes in the -globin locus through its six hypersensitive 
sites (HS). Five of these DNase I HSs are located 5’ of the -globin gene. HS 1, 2, 3, and 4, are 
erythroid specific and are distributed over about 15 kb. The final 5’ DNase I HS, HS 5, is 
sensitive to DNase I in many tissues (32) (26) (27). The sixth HS, 3’HS 1, is located downstream 
of the -globin gene. 5’HSs 2 – 4 appear to be the most important for globin gene regulation and 
each of these sites have a 200-300 bp highly conserved core (33) (34) (35). These cores contain 
binding sites for erythroid specific DNA binding proteins that are involved in transcriptional 




distinct from classic enhancers due to the fact it has regulatory influence over the entire -globin 
locus (31). In fact, it is characterized as a super-enhancer. It is given this classification because it 
is a large region that contains active chromatin features, like DNase I HSs, transcription factor 
binding, histone acetylation, and chromatin modifiers (37) (38).  
A separate function of the LCR that is important is its role in chromatin looping. Studies 
supporting this role provide evidence of the novel activity of the LCR. They show it loops to 
bring the HSs near each other in order to bind DNA regulatory factors and then bring them in 
contact with the -globin locus gene promoters (39) (36). Looping of the LCR changes through 
the different stages of development, binding the -globin promoter in fetal development and the 
-globin promoter postnatally, providing a possible explanation for globin switching. Although 
originally believed to be important for the timing of globin switching, studies opposing this role 
indicate that when the LCR is deleted in YAC mice they have reduced expression of the -
globin genes, but they are still expressed at the correct developmental time points (40) (41) (42). 
These findings indicate the LCR is not needed to help regulate the switches of globin gene 
expression but is needed for normal expression levels. A factor that is necessary to promote 
chromatin looping of the LCR to the -globin promoter is lim domain binding 1 (LDB1) protein. 
A region of LDB1 that is required for its function is its dimerization domain (DD). LDB1 is able 
to complex with GATA1 and TAL1 through its LIM-interacting domain (LID) which interacts 
with the LIM-only protein (LMO2). This then provides LDB1 interaction with the DNA-binding 
proteins GATA1 and TAL1 to provide LDB1 association with chromatin (43) (44).  
These studies also found in the absence of the LCR the DNase I-sensitive open chromatin 




transgenic mice or MEL cells had shown the 5’ HSs increased expression of the -globin genes 
(27) (45) (46) and had shown individual HSs were needed for forming an open chromatin state at 
the -globin locus (47) (48). It was not until the entire LCR was deleted from the murine -
globin locus and was shown the locus was still active and in an open chromatin conformation 
that researchers begin to consider the LCR is not needed for the open chromatin conformation 
seen at the -globin locus (40). Despite some uncertainty remaining about how the LCR 
functions, it is still well established that the LCR is a key regulatory element needed for 




Figure 2: The Human - and -globin Loci 
Depiction of the human globin genes and how the products from each chromosome combine to form 
the different globins. HBZ = ζ-, HBA2 = 2-, HBA1 = 1-, HBE = -, HBG2 = G, HBG1 = A-, 
HBD = -, and HBB = -globin.  
Top: The human -globin genes on chromosome 16. Bottom: The human -globin locus on 
chromosome 11. Middle: the ovals and their corresponding lines show how the combinations of these 







d. Hereditary Persistence of Fetal Hemoglobin (HPFH) 
HPFH is an asymptomatic condition that occurs in some individuals, where the HbF to 
HbA switch is not complete. This results in individuals having abnormally high levels of HbF, 
ranging from 5 – 80% (49). The condition seems to be benign with no noticeable phenotype. 
Additionally, coinheritance of a -hemoglobinopathy mutation with a HPFH variant can 
ameliorate the symptoms of the disease (50). Many variants that cause HPFH are found in the -
globin locus and the -globin gene (49) (50). One variant is a deletion in the 3’ region of the -
globin gene that removes a silencer element between the - and -globin genes; the result is that 
-globin expression is no longer repressed (51) (52) (53). A different deletion in the 3’ region 
Figure 3: Hemoglobin Switching and the Human -globin Locus 
Top: The synthesis of the globins from the time of conception, to birth, to adult life and the location at 
which the globin synthesis is taking place. Bottom: The -globin locus on chromosome 11. In order to 
better visualize when each gene is being expressed, the color of the curves correspond to the colors of 
the genes depicted in the schematic of the -globin locus. Adapted from Sankaran V. and Orkin S. 




brings enhancer elements in close proximity to the -globin gene; the enhancer now promotes -
globin expression (54) (55). Point variants in the -globin promoter are also responsible for 
causing HPFH. One of these variants is a C to T transition at -158, which creates a restriction site 
for XmnI (56). Another variant is a C to G mutation at -202 (57). These variants increase HbF to 
10 – 20% of the total hemoglobin. One final variant that causes HPFH is due to a non-
homologous crossover between the - and -globin genes and is called Hb Kenya. The crossover 
is in the second exons of the two genes between the codons for amino acids 80 – 87. It brings an 
enhancer element of the -globin gene near the -globin promoters which results in an increase 
in expression of HbF (50). There are multiple other point variants in the promoter and in 
regulatory regions of the -globin gene that cause HPFH; the variants listed here are examples of 
the variety of variants that can cause HPFH (50). More recently, it has been found that at least 
50% of the variants that cause HPFH are found in the HBSIL-MYB, BCL11A, and KLF1 genes 
(58). The HBSIL-MYB region on chromosome 6q23 is a quantitative trait locus (QTL) for 
HPFH identified through genome wide linkage studies (59) (60) (61) (62) (63). A genome wide 
association study (GWAS) performed in a population of Sardinian individuals with a high 
prevalence of HPFH identified a causal SNP in BCL11A (64). This variant will be discussed 
more in Chapter 2.3.b. Variants in KLF1 also cause HPFH (65) (66) (67) (58). These variants 
will be discussed more in Chapter 4.1.a, but it should be noted that the first KLF1 variant found 
to cause HPFH was identified in a Maltese family. The identified variant is the nonsense variant 
p.K288X; it ablates the DNA binding domain (58). The evidence that HPFH is benign, 
ameliorates -hemoglobinopathies, and is a result of numerous variants in various locations 
introduces the possibility that reproducing these variants to reactivate the -globin gene could be 




the factors that bind to these sites, rather than the DNA itself, as a potential treatment. This will 
be discussed more in Chapter 8.  
3. β-Hemoglobinopathies 
These diseases are the manifestation of improper forms or amounts of HbA as a result of 
mutations in the -globin gene. The most common β-hemoglobinopathies are Sickle Cell Disease 
(SCD) and β-thalassemia.  
a. Sickle Cell Disease (SCD)  
SCD affects approximately 100,000 Americans, with prevalence in about 1 in 365 
African-American births and 1 in 16,300 Hispanic-American births (68). The term SCD refers to 
all the genotypes that cause a clinical symptom. Sickle-cell anemia (SCA) is the most common 
form of SCD (69). Individuals who are carriers of SCD are said to have Sickle-Cell Trait (SCT). 
The prevalence of having SCT in the African-American population is 1 in 13. SCA is an 
autosomal recessive disorder caused by the substitution of a thymine for an adenine, causing for 
the coding of a valine instead of a glutamine in position 6 of the Hb beta chain (70). To have 
SCA an individual must be homozygous for this mutation. This results in the affected individual 
having Sickle-cell hemoglobin (HbS). Being homozygous for this substitution results in the traits 
associated with SCA; instead of having healthy, round RBCs, affected individuals have RBCs 
that are sickled. This results in the RBCs becoming hard and sticky, which causes them to get 
stuck in blood vessels and clog blood flow. The sickled blood cells also die early, which causes a 
shortage of RBCs (68). This change in morphology and reduction of RBCs is what reduces their 




The treatment most often used for SCA is the drug hydroxyurea (HU). Hydroxyurea was 
first shown to be an effective treatment for individuals with SCA in 1984 (71). A large clinical 
trial completed in 1995 confirmed HU as a viable treatment for ameliorating pain crises and for 
increasing HbF levels (72) (73).  It has been proven to reduce the frequency of painful episodes 
in SCD patients and the need for blood transfusions by 50%. Another drug that is used to treat 
SCA is L-glutamine, which has only begun to be used more in the last three to five years. It has 
been shown to reduce the number of sickle cell crises, vaso-occlusive painful events, the need for 
hospitalization, and erythrocyte morphology; however, it has not been shown to increase HbF 
and its mechanism of action is unclear (74). Increasing HbF is important because it results in an 
increase in the ratio of - to -globin in the individual. This is crucial because it results in the 
individual having a higher percentage of circulating -globin which can function in place of their 
abnormal -globin, reducing the complications associated with SCA. 
 The  known mechanism of action by which HU induces HbF is by inhibiting 
ribonucleotide reductase from transforming ribonucleosides into deoxyribonucleosides, which 
reduces DNA synthesis (75). This is good because inhibited DNA synthesis causes cytotoxic 
suppression of erythroid progenitors and cell stress signaling which leads to recruitment of 
erythroid progenitors to make more HbF (75). It could also work by reducing inflammation by 
reducing the bone marrow’s production of neutrophils. Neutrophils are part of the immune 
system and promote inflammation. Patients with SCA tend to have higher neutrophil counts than 
controls and their neutrophils tend to be more active in promoting inflammation. Treatment with 





HU treatment was initially reserved for treatment in older patients because there were 
concerns about giving it to children. But, clinical trials using HU treatment in children and 
infants have shown it is just as safe and effective as in adults (77) (78) (79). HU treatment has 
been shown to be the most effective available treatment for SCA, but unfortunately it does not 
work for every patient (80). Additionally, there have been concerns about its long-term use. To 
address these concerns, there have been many studies performed that show there are now patients 
who have been on HU treatment for 10-20 years who have had sustained benefits, and there is 
evidence HU treatment is associated with improved survival (81) (82) (83) (84). It is important to 
note that HU is a good treatment for ameliorating RBC sickling, but it does not eliminate RBC 
sickling. This establishes it as a partial treatment for SCA, but is certainly not a cure. While HU 
continues to be the best method available for treating SCA patients, the issues and questions 
presented here indicate the need for additional treatment methods. 
b. β-thalassemia  
β-thalassemia is a common genetic disorder worldwide that also reduces the production 
of hemoglobin. About 60,000 symptomatic individuals are born each year, and the estimated 
effected global population is 80 to 90 million (85). Causes of -thalassemia are a result of single 
nucleotide substitutions or deletions or insertions of oligonucleotides leading to a frameshift; -
thalassemia is rarely the result of deletion of the gene (86). The type of β-thalassemia an 
individual has determines the severity of their disease. There are three types: β-thalassemia major 
(β0/β0), intermedia (β0/β+or β+/β+), and minor (β/β+ or β/β0) (85). Individuals affected with 
β-thalassemia major have no β-globin and need consistent medical treatment starting in the first 
few years of life. Individuals affected with β-thalassemia intermedia have reduced β-globin 




Individuals with β-thalassemia minor are usually asymptomatic but occasionally have mild 
anemia (85).  
In individuals with major or intermedia -thalassemia, their lack or reduction of 
hemoglobin leads to a reduction of oxygen in the body, resulting in weakness, fatigue, and an 
increased risk of blood clots (87). Additionally, the ineffective erythropoiesis in these patients 
can cause enlarged organs, such as splenomegaly (enlarged spleen), hepatomegaly (enlarged 
liver), and lymphadenitis (enlarged lymph nodes), due to extramedullary erythropoiesis – 
hematopoiesis that occurs in organs outside of the bone marrow; and misshapen bones, such as 
deformities of the long bones in the legs and craniofacial changes, due to expansion of the bone 
marrow (86) (85). A factor contributing to the severity of anemia in β-thalassemia patients is an 
imbalance of -globin. This imbalance happens due to the lack of -globin present to form 
normal tetramers. The excess -globin precipitates in erythrocytes causing damage to developing 
and mature red cells. This results in the premature destruction of erythrocytes in the bone 
marrow, which causes the observed anemia (88).  
A common method used for treating β-thalassemia is blood transfusions. The objective of 
blood transfusions is to reduce the anemia of an individual by replenishing their RBCs so they 
are able to carry more oxygen (85) (89). Individuals with major β-thalassemia need transfusions 
every few weeks, but individuals with intermedia β-thalassemia need transfusions less 
frequently. A side effect to frequent blood transfusions is iron overload. This buildup of iron 
occurs mainly in the thyroids, liver, and heart and makes it hard for these organs to function 






-thalassemia is another inherited blood disorder, except the missing/reduced globin is -
globin instead of -globin. It mainly affects people in the Middle East, Southeast Asia, and the 
Mediterranean Basin (90). The normal genotype is /. The forms of -thalassemia are 
expressed as α0 and α+, where α0 produces no  chains from either one or both affected 
chromosome(s) (--/ or --/--) and α+is missing one of the linked pairs of -globin genes (-/- 
or -/) (88). Erythropoiesis is more effective in -thalassemia than in -thalassemia, but red 
cell survival is still short. Like with -thalassemia, in -thalassemia the complications associated 
with it are due to the imbalance of  and  chains that cannot form tetramers because of the 
reduction of  chains present. In the fetus the excess -globin forms tetramers (γ4) and is 
referred to as Hb Bart’s. After birth it is the excess -globin that forms tetramers (β4) and is 
referred to as HbH. These tetramers have a high affinity for oxygen and do not let go of their 
bound oxygen when necessary, which contributes complications associated with -thalassemia. 
Hemolysis – the destruction of RBCs – is the main cause of anemia in -thalassemia patients 
(88). Hemolysis occurs because of the -globin tetramers of HbH; HbH is unstable and the 
tetramers precipitate in the RBCs, which causes them to be prematurely destroyed (91) (92). -
/ heterozygotes have less severe symptoms and no detectable HbH. -/- heterozygotes 
have very low levels of HbH and a mild phenotype. -/-- have a more severe phenotype and 
higher levels of HbH. --/-- homozygotes is the most severe form that results in stillbirth; it is 
referred to as Hb Bart’s hydrops fetalis (93). The phenotypes most often seen with HbH are 





d. Treatment for -hemoglobinopathies  
The only cure for both SCA and β-thalassemia is for patients to receive a bone marrow 
transplant (BMT). BMTs are performed more frequently in -thalassemia patients than in SCA 
patients because BMT is reserved for SCA patients with severe complications where the benefits 
of transplant outweigh the risks, like graft-vs-host-disease (94) (95). Graft-vs-host-disease 
(GVHD) occurs when the donors bone marrow T-cells view the recipient’s cells as foreign and 
attack them (96). Acute and chronic GVHD ranges from 6-50%, and results in death in 5-8% of 
all treated individuals  (97) (85). A major limitation to receiving a BMT is that most patients do 
not have a matched sibling who can be a donor and unrelated donors are rarely used because it is 
hard to find a perfect match (85). If a donor is found, the recipient still has a risk of developing 
GVHD. Another factor contributing to the likelihood of a patient receiving a BMT is their 
location. More transplants are performed in Europe, especially in Italy, compared to elsewhere. 
This is because there are three centers in Italy that have focused on BMTs since the first one was 
performed on a -thalassemia patient in 1982 (88). Other centers have been open around the 
world since then, but the Italian groups are the most experienced in this procedure. This has 
resulted in the development of better pre- and post-transplant procedures that contribute to 




Chapter 2 – Regulation of the Gamma and Beta Globin Genes 
 
 
1. Regulation by Transcription Factors and Chromatin Modulators 
The - and -globin genes are regulated by elements in their promoters. Both genes have 
CAAT, TATA, and CACCC elements (100). -globin has a duplication of the CAAT box and -
globin has a duplicated CACCC box (100) (101) (Figure 4). The LCR is also important for 
chromatin looping. The LCRs role in gene expression was discussed in detail in Chapter 1.2.c, 
but it is important to note the significance of the DNAse I 5’HSs in the regulation of - and -
globin. The 5’HSs contain DNA binding sites for DNA transcription factors like KLF1 and 
GATA1 (32) (102). Many of these transcription factors will be discussed in part 2 of this chapter.  
 
 
Figure 4: Regulatory Elements of the - and -globin genes 
The CAAT, TATA, and CACCC elements of the - and -globin genes. Above the element sequences 
are the regulatory factors likely to bind at that site. EKLF = KLF1. Adapted from Cao A. and Moi P. 




2. Erythroid-specific Transcription Factors 
a. GATA1 
GATA1 was first discovered in 1988 through studies of the -globin promoter. One study 
identified it as a protein present only in erythroid cells at chicken globin promoters (103) and 
another study saw the -globin gene enhancer contains multiple regions for binding GATA1 
(104) (Figure 4). This introduced GATA1 as an important factor for transcription of the -globin 
genes. The gene is located on the X chromosome (105) and the protein contains two zinc finger 
DNA binding domains. These domains are the carboxyl terminal finger (C-f) and the amino 
terminal finger (N-f). They are responsible for attaching GATA1 to its target gene and for 
promoting GATA1 interactions with its cofactor, friend of GATA1 (FOG1), to activate 
transcription (106) (107). GATA1 is highly expressed in hematopoietic cells and is required for 
erythropoiesis (108). GATA1 is able to perform these functions through its interaction with 
FOG1. They work to induce differentiation in hematopoietic cells by activating genes that 
promote mature cell forms and repressing genes that work to maintain an undifferentiated cell 
state (109). GATA1 and FOG1 are both necessary for normal development; when either is 
missing there is a failure to produce mature RBCs which results in the death of mice in utero due 
to severe anemia (110) (111) (112). Mutations can also occur in either one of these genes that 
result in a number of diseases, like X-linked thrombocytopenia and acute megakaryoblastic 
leukemia associated with Trisomy 21 (113). 
One of the blood disorders that results from a GATA1 mutation is X-linked 
thrombocytopenia (XLT). This is the result of a missense mutation in GATA1 that reduces its 




this disease, but they all are a single amino acid substitution in the N-f section of GATA1 (114) 
(115) (116) (117) (118). These mutations reduce the platelet number and make them less 
effective at clotting. Therefore, individuals who have XLT often present with a tendency for 
hemorrhaging. Patients with XLT also present with varying forms of anemia, ranging from mild 
to dependence on blood transfusions (113). A second blood disorder also caused by a missense 
mutation is X-linked thrombocytopenia with thalassemia (XLTT). In this disorder the mutation 
affects the section of N-f that stabilizes GATA1 binding with palindromic DNA; it does not 
affect the interaction of GATA1 with FOG-1 (119). This reduces the ability for GATA1 to 
promote hematopoietic cell differentiation. Individuals with XLTT share many of the same 
clinical features as individuals with XLT, but in addition individuals with XLTT have mild -
thalassemia (120). 
b. Krüppel-Like Factor 1 (KLF1)  
KLF1, originally EKLF (erythroid Krüppel-like factor) because it is expressed in 
erythroid cells, is a transcription factor with three zinc fingers first discovered in 1992 (Figure 5). 
KLF1 was found by enriching for genes expressed in an murine erythroleukemia (MEL) cell line 
but not expressed in a mouse monocyte-macrophage cell line (121). It was named because 
investigators found it has three zinc finger motifs that are similar to those in the Krüppel gene in 
the fruit fly. Its name was later changed from EKLF to KLF1 when it was realized it is the first 
member of a 17-member family of Krüppel-like transcription factors (122). Originally KLF1 was 
thought to be necessary only for activation of the adult β-globin locus, but later it was found to 
be necessary for activating genes in many other erythroid pathways required for erythropoiesis 
(123) (124). One of the more frequently studied roles of KLF1 is its activation of the β-globin 




4). This allows KLF1 to transcriptionally activate the β-globin gene (121). KLF1 interacts with 
the proteins p300, CBP, and PCAF, which have histone acetyltransferase activities. p300 and 
CBP acetylate KLF1 in its transactivation domain (TAD) to enhance its transcriptional activation 
at the -globin promoter. PCAF works in opposition of p300 and CBP; it inhibits KLF1 
transcriptional activity by interacting with KLF1 at the same regions as CBP and p300 which 
inhibits their interaction with KLF1 (125). KLF2, or lung KLF (LKLF), is a member of the KLF 
family that has 88% homology to the zinc fingers of KLF1, but they share little homology 
outside of this region (126). KLF1 and KLF2 can partially compensate for each other when 
regulating the mouse embryonic -globin genes (127) (128). It is predicted they are able to 
compensate for each other by binding to the same or similar DNA sequences due to their highly 
homologous zinc fingers (126).  
Through its interaction with p300 and CBP, KLF1 plays an important role in maintaining 
an open chromatin structure at the -globin locus. Open versus closed chromatin conformation is 
important for determining if a gene is transcribed or not. When chromatin is open it is more 
easily accessible to the transcription apparatus, including RNA polymerase, and more likely to 
be transcribed (129). p300 and CBP acetylate histones, which is correlated with open chromatin. 
Additionally, the three zinc fingers of KLF1 allow it to bind to CACCC elements of the gene 
promoters of the -globin locus to help create its active chromatin structure (130) (128). It also 
binds to the LCR HSs. When KLF1 is present it is able to bind to CACCC elements and the LCR 
HSs to form the active chromatin hub (ACH), which is essential for transcription. The ACH is 
comprised of the upstream and downstream HSs of the LCR, the actively expressed globin genes 
of the -globin locus, and KLF1 (39) (131). Without the presence of KLF1, the active globin 




chromatin hub (CH) (132) (133) (131). The ACH cannot form when KLF1 is knocked out, 
changing the positioning of the LCR in relation to the genes, as discussed in the next paragraph. 
This in turn results in reduced transcription of the -globin locus.  
Loss of KLF1 results in a closed chromatin state through multiple mechanisms. The LCR 
contains HSs, which are crucial for maintaining -globin gene expression. Loss of KLF1 affects 
the formation of the HSs at the -globin gene (134). This results in the loss of the LCRs ability to 
regulate -globin locus expression. Without KLF1, chromatin looping to position the LCR and 
globin genes in close proximity can no longer occur (131). KLF1 expression is correlated with 
the presence of histone H3K9Ac and H3K4me3 at the globin locus, which are associated with 
open chromatin and active transcription, respectively. When KLF1 is ablated, these marks are no 
longer enriched and the open chromatin state at the -globin locus is diminished (128). The 
effect that loss of KLF1 has on these processes results in the loss of transcription at the -globin 
locus. 
To prove KLF1 is necessary for transcription of the β-globin gene it was knocked out in 
mice. This resulted in embryonic death by day 16 (E16) due to the development of -thalassemia 
(123) (135). The time point at which the embryos die is significant; it is when the switch from 
embryonic to adult globin is complete. KLF1 null embryos appear normal during the yolk sac 
stage, but between E11 and E16 the embryos become more and more anemic until it results in 
the loss of the embryo. The progressive increase in anemia starting at E11 matches the beginning 
of the switch from embryonic to adult globin.   
There are a number of variants associated with KLF1 that affect transcription of the gene, 




paragraph above, loss of KLF1 in mice is lethal due to the severe anemia caused from the loss of 
expression of -globin. Additionally, mutations in the CACCC box of the -globin gene result in 
reduced affinity for KLF1. This results in a lack of binding by KLF1 and reduced expression of 
the -globin gene, resulting in -thalassemia (136). A condition that is caused by KLF1 variants 
is HPFH. HPFH was described in Chapter 1.2.d. A genome-wide SNP scan performed in 2010 
on members of a Maltese family, in which 10 of 27 members have HPFH, identified a nonsense 
variant, p.K288X, in the KLF1 gene (58). This mutation ablates the zinc finger domain which 
prevents KLF1 from binding to DNA, therefore reducing its activation of the -globin gene and 
allowing the -globin gene to be expressed. This results in an increase in HbF and causes HPFH. 
Only individuals that are heterozygous for the p.K288X mutation experience increased HbF 
levels, ranging from 3.3 – 19.5%.  
There are two anemia condition caused by KLF1 variants. KLF1 variants cause 
nonspherocytic hemolytic anemia (NSHA). NHSA results in short survival of RBCs that have 
abnormal morphology and hemolysis. Heterozygotes for a small in-frame deletion that interferes 
with KLF1 function (class 2 variant) and a stop codon or frameshift mutation that causes a 
shortened KLF1 protein that lacks the DNA binding domain (class 3 variant) usually have this 
disease (137). A final disorder caused by KLF1 variants is congenital dyserythropoietic anemia 
(CDA). Patients with CDA have poor erythropoiesis, hemolysis, anemia, and erythroblasts with 
abnormal morphology. There are four types of CDA, but only type IV is caused by a KLF1 
variant. There is a single base transition in exon 3 of KLF1 that results in an amino acid change 
in the second zinc finger. This area of the zinc finger is essential for KLF1 binding to its DNA 
motif, so the variant results in improper expression of the -globin gene (138) (139) (140). 




known disorders KLF1 variants can cause, and there are likely many more disorders caused by 
KLF1 variants researchers have yet to discover. This shows just how involved and important 




3. Non-erythroid specific Transcription Factor 
B cell CLL/lymphoma 11A (BCL11A) 
BCL11A was initially identified as the murine homologue Evi9 in 1999. In mice the 
locus was discovered to be a site of retroviral integration which induces myeloid leukemias (141) 
(142). One study performed in 2000 identified the human homologue by isolation of isoforms 
expressed in CD34+ myeloid precursor cells (143). Another study in 2000 also found the 
BCL11A gene. This study found BCL11A to be involved in a translocation involving the 
immunoglobulin heavy chain (IGH) locus that causes aggressive B cell lymphocytic leukemias 
Figure 5: KLF1 Domains and Variants 
Two transactivation domains (TAD) are located at the N-terminus and three zinc fingers (ZF) located 
at the C-terminus. Class 1 variants are green; class 2 and class 3 variants (variants that can be 
associated with CDA IV) are in blue and red, respectively. The blue highlights are histidine and 
cysteine residues involved in zinc coordination, yellow highlights are KLF1 residues that contact 




and that the region in which BCL11A is located is often overexpressed in B cell lymphomas and 
Hodgkin disease (144). All of these studies introduced BCL11A as a zinc finger transcriptional 
repressor and established it to be involved in B-cell malignancies as an oncogene (144). Then, a 
GWAS performed in 2007 identified BCL11A as a key repressor of -globin (64).  
This GWAS had 4,305 participants and tested association with 362,129 common SNPs. 
The participants chosen for this study were Sardinians; this population was selected because -
thalassemia occurs at a high frequency with co-inheritance of HPFH, so they are a good 
population for identifying alleles associated with HPFH (64). The GWAS identified a SNP in the 
BCL11A gene to be strongly associated with the HbF phenotype. This indicates that when a 
variant is present in the BCL11A gene it allows for higher production of -globin because the 
gene cannot function as normal to repress the -globin gene. Like KLF1, knockout of BCL11A 
in mouse models is lethal, however BCL11A null mice die postnatally (145) (146). Erythroid-
specific knockout of BCL11A in transgenic mouse models results in reduced silencing of human 
-globin and does not result in anemia or embryonic death (147) (146). One study showed 
erythroid-specific knockout of BCL11A in transgenic mice was able to rescue the phenotype of a 
SCD mouse model. These compound transgenic mice, having the human sickle -globin locus, 
have normal RBC counts, normal hemoglobin content, no sickled cells, normal red cell survival, 
and reduced damage to the spleen (146). These findings prove erythroid-specific targeting of 
BCL11A is a valid target as an approach to increase -globin levels as a potential treatment for 
patients with -hemoglobinopathies. 
These studies showing that reduction of BCL11A expression increases -globin 




clinical trials. One clinical trial, initiated in 2018, is testing the use of ST-400 as a treatment for 
individuals with transfusion-dependent -thalassemia (TDT) (148). ST-400 is a cell therapy that 
uses gene editing to modify a patient’s own hematopoietic stem cells (HSCs) to produce more 
HbF and then infusing these gene edited cells back into the patient. In this trial, the patients’ cells 
are enriched for CD34+ cells, then the cells are transfected with mRNA encoding the zinc finger 
nucleases (ZFNs) that have binding sites flanking a precise location in the BCL11A gene, in 
order to disrupt an enhancer and decrease gene expression. This location that is disrupted is the 
GATA-binding region of the intronic erythroid-specific enhancer (BCL11A ESE). These edited 
cells are then infused back into the patient (149) (150). Preliminary results from this clinical trial 
have shown increased HbF levels (remaining elevated at 6 months post-infusion) and on-target 
indels present in peripheral blood mononuclear cells (PBMCs) in three of the six patients who 
have undergone treatment. All three of these patients still require intermittent blood transfusions 
though.  
The second clinical trial, also initiated in 2018, is focused on a treatment for SCD. The 
aim of this trial is also to perform gene therapy by harvesting the patients’ bone marrow and 
enriching it for CD34+ cells, but they use a different gene therapy method. They transduce the 
cells with a lentiviral vector containing a shRNA that targets BCL11A. These edited cells are 
then infused back into the patient (151). Preliminary results have shown two of the three patients 
(9, 10, and 18 months post transfusion) who received treatment have stopped blood transfusions, 
with the third having to resume them because they had progressive narrowing of the carotid 
artery. The patients now produce normal hemoglobin levels and HbF levels are high enough to 




Both of these clinical trials are still in the early stages, but they both show promising 
results for their treatments. As they enroll more patients and have studied them for a longer 
period of time, it will be interesting to see if these methods will be viable for effective treatment 
of individuals with a -hemoglobinopathy. A downside to developing gene editing treatments is 
they will not be feasible treatments for individuals affected with a -hemoglobinopathy in third 
world countries, as they lack many of the resources needed to perform the treatments. Gene 
therapy will also be expensive, which will greatly limit its availability. These limitations will be 
discussed more in Chapter 8. 
KLF1 regulates the BCL11A gene (153) (154). When KLF1 is knocked down the level of 
BCL11A is thereby reduced. KLF1 directly activates β-globin production, as discussed in 
Chapter 2.2.b, and indirectly represses -globin production by promoting BCL11A to repress the 
-globin gene. These genetic interactions are responsible for reducing HbF (Figure 6). KLF1 is 
able to regulate BCL11A expression by binding to the BCL11A promoter, which has several 
CACC boxes that are KLF1 binding sites (58) (153).  
However, it is unclear exactly how BCL11A interacts with the -globin gene to repress 
transcription. There was debate about whether BCL11A binds DNA directly and what 
sequence(s) it recognizes (155). Previous work suggested BCL11A acts within the -globin 
locus at a distance to the -globin promoter in order to repress it; the two proposed locations 
were at the 5’HS 3 and between the - and -globin genes (156) (157) (155). The current 
proposed mechanism provides evidence that BCL11A binds to the -globin promoter at a 
TGACCA motif from nucleotides -118 to -113 which prevents the occurrence of chromosomal 




globin gene and promote its transcription, therefore increasing the ratio of HbA to HbF. When 
BCL11A is not present it cannot interfere with looping of the LCR to the -globin gene. This 
causes the LCR interaction to shift to the -globin gene to promote its transcription which 




4. Non-Erythroid Specific Chromatin Modifier 
Methyl Binding Domain 2 (MBD2) 
MBD2 is a member of the MBD family of proteins that also includes MeCP2, MBD1, 
MBD3, and MBD4 (158) (159). These proteins were all discovered as a result of the discovery of 
Figure 6: KLF1 Promotes BCL11A to Repress -globin Gene Expression 
The left shows the proportion of - to -globin when EKLF1 (KLF1) levels are low. Low levels of 
KLF1 cannot promote BCL11A to repress -globin gene expression and cannot promote -globin 
gene expression. This results in predominantly HbF. The right shows the proportion of - to -globin 
when KLF1 levels are high. The high levels of KLF1 promote BCL11A to repress -globin gene 
expression and promotes -globin gene expression. This results in predominantly HbA. Adapted from 




MeCP1 in 1989 (158). MeCP1 is a methyl-CpG binding protein that complexes with other 
methylated DNA sequences. Further study led to the discovery of MeCP2 in 1992. Subsequently,  
MBD1 was identified in 1997 (160) and then the other MBDs in 1998 (159). All of these 
proteins, except MBD3, bind to methylated DNA. MBD2 is able to bind to densely methylated 
CpG islands through recruitment of the Nucleosome Remodeling and Deacetylase (NuRD) co-
repressor complex. This allows MBD2 to repress transcription of multiple genes (161).  
The NuRD complex has seven subunits. The histone deacetylase core proteins HDAC1 
and HDAC2 and the histone binding proteins RbAp48 and RbAp46 make up the core complex. 
The remaining three subunits are comprised of either MBD2 or MBD3, chromodomain helicase 
DNA binding protein CHD3 (Mi2) or CHD4 (Mi2), and the metastasis-associated proteins 
MTA1 or MTA2 or MTA3 (162). This group of proteins provides both histone deacetylase and 
chromatin remodeling ATPase activities that are used for repressing transcription (163)(164). 
Through the interaction of MBD2 with NuRD it is able to silence the -globin gene. 
It was shown in 2006 that MBD2 is a regulator of -globin gene silencing in adult human 
βYAC transgenic mice (165). This study showed adult βYAC transgenic mice with an MBD2 
knockout have higher -globin expression than wild type (WT) mice, indicating that MBD2 
causes transcriptional repression of the -globin gene. MBD2 null mice have only minor 
phenotypic effects – lower body weight than average and changes in B-cell differentiation. The 
knockout of MBD2 does not alter the viability of embryos or their fertility (166) (167). Increased 
-globin expression is also seen when human erythroid cells are depleted of MBD2 (168) (169). 
The proposed mechanism by which MBD2 represses -globin has to do with the structure of 




(G/R domain), MBD, an intrinsically disordered region (IDR), and a coiled-coil domain (170). 
The coiled-coil domain binds to p66α of NuRD, forming a MBD2/NuRD complex; this recruits 
CHD4 which results in gene silencing (171). The IDR is also involved in this process by 
recruiting the histone deacetylase core components (HDCC), comprised of MTA2, HDAC2, and 
RbAp48, as well as recruiting the coiled-coil domain which interacts with p66α and then recruits 
CHD4 (170). Disruption of the IDR prevents formation of the MBD2/NuRD complex and results 





Chapter 3 – Erythroid Model Systems 
 
 
1. Cell lines 
Cell lines are cells that have been isolated from an organism that continue to proliferate 
in culture outside of their host environment. They are important because they are easier to 
maintain than animal models and they provide a system that can be manipulated to allow for the 
study of different disorders, diseases, and biological processes. Cell lines have proved a useful 
tool for studying globin gene regulation, erythropoiesis, and hemoglobin disorders. Many cell 
lines have been used in the course of studying these topics; some of those cell lines will be 
discussed here. 
a. Murine Erythroleukemia (MEL) cells 
A virus that is able to induce murine leukemia was discovered in 1957 and is called the 
Friend virus (172). The MEL cell line was established in 1966 from leukemic spleens induced by 
the Friend virus (173). MEL cells can be differentiated and synthesize hemoglobin when treated 
with dimethyl sulfoxide (DMSO) (174) (175). The creation of this cell line was important 
because it was the first erythroid cell line created that was able to be cultured and passaged long 
term. This, and the ability to induce the cell line to produce hemoglobin, introduced the 
possibility to study globin gene regulation.  
The availability of MEL cells allowed for the discovery that the accumulation of 
hemoglobin and globin mRNA after differentiation is a result of the transcriptional activation of 
the globin genes. This study also determined that termination of transcription occurs in a specific 




Studies using MEL cells also led to the findings that the -globin gene is located on human 
chromosome 16 (177) and the β-globin gene locus is located on human chromosome 11 (178). 
Another study showed that even though the - and -globin genes are located close to one 
another on chromosome 11, only -globin is expressed in MEL hybrid cells. This led them to 
conclude that there is different regulation between the - and -globin genes and it must involve 
globin specific regulation factors (179).  
b. K562 cells 
K562 is a cell line that was established in 1973 from a chronic myeloid leukemia patient 
(CML) (180). K562 was the first established human cell line in which the erythroid lineage could 
be studied. In 1979 it was shown K562 cells can be differentiated into RBCs in vitro (181). In 
1980 it was confirmed that K562 cells lack several properties of adult and possess multiple 
characteristics of embryonic or fetal erythroid cells (182). From these observations they 
concluded K562 cells represent early fetal and embryonic erythroid progenitor cells (182) (183) 
(184). They have an intact β-globin gene but it is not expressed (185) (186) (187). The status of 
K562 cells provided the opportunity to study the mechanisms of embryonic and fetal globin 
development. They also provided a tool to study globin switching and the regulatory mechanisms 
of the β-globin gene. Because β-globin is not made in these cells, they provided a model to study 
negative control of the -globin gene.  
K562 cells were also used to identify important regulators of the globin genes. In 1990 
K562 cells were used to study the function of the -globin promoter. This study examined three 
mutations in the -globin promoter associated with HPFH. They found none of these mutations 




phenotype (188). In 1997 K562 cells were used to show guanosine 5’-triphosphate (GTP) can be 
used to induce differentiation and proliferation (189). A study done in 2000 used this knowledge 
to show that GTP differentiation in K562 cells increases fetal globin mRNA expression, 
increases the binding capacity of the transcription factor GATA1 to the -globin promoter, 
increases GATA1 mRNA and protein expression, and GTP treatment can stimulate the -globin 
promoter (190). These findings provided an approach that could be studied as a method to 
increase -globin expression as a treatment for β-hemoglobinopathies. While K562 cells led to 
some discoveries regarding the globin genes, they are not an optimal model system. K562 cells 
are derived from cancer cells, so they have abnormal genomes which can influence the 
expression of the globin genes and give an inaccurate understanding of their function.  
c. Human Erythroleukemia (HEL) cells 
The HEL cell line was established in 1982 from the peripheral blood of a Hodgkin’s 
disease patient who developed erythroleukemia (191). This same study established that HEL 
cells can be induced to express -globin but not -globin.  
Studies involving HEL cells helped characterize multiple HPFH mutations and helped to 
uncover how the altered activity due to these mutations increases HbF (49). The same study 
detected multiple binding sites for nuclear proteins in the promoter region of the -globin gene. 
For example, CAC1 and CAC2 are important to transcription because mutations in their 
sequences reduce binding to the -globin CACCC (49). The CACCC box is a regulatory element 
upstream of the β-globin gene first discovered to be important for transcription in 1984 from 
studies in individuals with β-thalassemia (192). HEL cells also helped uncover a mechanism by 




for individuals with β-hemoglobinopathies in 1984 (71). A 2001 study shed light on the 
mechanism by which HU treatment works. It found HEL cells can be induced to express the β-
globin gene via HU treatment and that GATA1 plays a role in inducing the β-globin gene in the 
HU treated cells and promotes cell differentiation. They also showed that GATA2 inhibits the 
differentiation of HEL cells (193). HEL cells have been useful for studying important regulatory 
regions of the globin genes and the role of transcription factors, but like K562 they are not a 
good model for studying hemoglobin switching because they were derived from cancer cells. 
d. Human Umbilical Cord Blood Derived Erythroid Progenitor (HUDEP-2) cells 
The HUDEP cell lines were established in 2012 and, as the name suggests, were derived 
from human umbilical cord blood. They are immortalized human erythroid progenitor cells that 
are able to produce RBCs upon differentiation (194). They were immortalized through a process 
whereby CD34+ cells were collected from umbilical cord blood (UCB) and cultured with SCF, 
TPO, and FLT3-L cytokines for 1 day. These cells were then infected with a lentiviral vector that 
contained the Tet-inducible HPV16-E6/E7 system. One day after infection the cells were 
cultured with SCF, EPO, and DEX cytokines for 4 days. Then, non-adherent cells were collected 
and cultured with SCF, EPO, DEX, and DOX for over 100 days with regular media changes 
(194). These proliferated cells established the immortalized HUDEP cell lines. 
There are three HUDEP lines: HUDEP-1, HUDEP-2, and HUDEP-3. The HUDEP-1 line 
has very little -globin mRNA before and after differentiation but has a 12-fold increase in -
globin mRNA after differentiation. The HUDEP-2 line has very little -globin mRNA before and 
after differentiation but has a 6-fold increase in -globin mRNA after differentiation. The 




fold increase in -globin mRNA after expression (Figure 7). Additionally, the HUDEP-2 line is 
the only line of the three that expresses BCL11A. The HUDEP-2 line is used in studies more 
often than the other two HUDEP lines. HUDEP-2 cells are a useful model that is used in many 
studies discussed throughout this thesis. The establishment of the HUDEP-2 line was important 
to the study of erythropoiesis, hemoglobin, and -hemoglobinopathies; it was the first line 
created that displays adult erythropoiesis because they express mostly -globin once 
differentiated (194). 
HUDEP-2 cells have been useful for studying the variants involved in causing SCA, 
HPFH, and -thalassemia and applying this knowledge to develop treatments for these diseases. 
In 2016, CRISPR-Cas9 was used to introduce an HPFH variant in HUDEP-2 cells and this 
resulted in an increase in HbF that was sufficient to ameliorate morphology of SCD (195). More 
recently, Cas9 sgRNA and sgRNA RNP electroporation were used to create HPFH variants in 
the human -globin promoter and resulted in an increase in -globin expression (196). HUDEP-2 
cells have also been used to generate sickle cell anemia and -thalassemia cell lines via CRISPR-
Cas9 editing (197) (198). These cell lines exhibit the phenotypes for sickle cell anemia and -
thalassemia and therefore provide an in vitro system in which trials can be performed testing new 
treatments. All of these studies are introducing potential new targets for treating -
hemoglobinopathies. 
HUDEP-2 cells have also been useful for studying many of the transcription factors 
involved in globin gene regulation. Studies using these cells have contributed to the knowledge 
of how KLF1, BCL11A, and MBD2 – as well as other transcription factors – mediate  and -








Cell lines have proved a useful tool for studying all kinds of diseases, disorders, and 
biological functions, including those involving hemoglobin. MEL and HUDEP-2 cells are adult 
cell models, and K562 and HEL cells are embryonic and fetal cell models, respectively. This 
provides researchers the opportunity to study the expression of the globin genes at every stage of 
development. Some drawbacks associated with these models are that MEL cells are of mouse 
origin, so there are differences in some globin expression and in timing of hemoglobin switching, 
and that neither K562 nor HEL cells express the β-globin gene. While K562 and HEL cells 
addressed the issue that MEL cells are not of human origin, they cannot be used as models to 
study β-globin gene expression. The creation of the HUDEP-2 cell line addressed both of these 
issues – they represent adult erythropoiesis and are of human origin. The benefits of each line are 
Figure 7: - and -globin Gene Expression in HUDEP-2 cells 
qRT-PCR results for the expression of - and -globin in the different HUDEP-2 cells lines. There is 
about a 5-fold increase in -globin gene expression after differentiation, but very little -globin gene 
expression before and after differentiation. Expression for the HUDEP-2 cell line is in the black box. 
B = before differentiation; A = after differentiation. FL = human fetal liver. CB = cord blood (CD34+ 




that they fill a hole the other lines possess: K562 cells were the first established human cell line 
and are useful for studying embryonic globins, HEL cells are useful for studying fetal globins, 
MEL cells are useful for studying adult globins, and HUDEP-2 cells are useful for studying adult 
globins in human cells. Studies involving these four cells lines have led to numerous findings 
contributing to the field of knowledge on this subject. A few of these discoveries include 
determining the human chromosomal location of the α- and β-globin genes, determining the 
location and function of the -globin promoter, providing a starting point for understanding how 
treatment with HU works, and delving deeper into understanding the genetics behind -
hemoglobinopathies so better treatments can be developed.  
2. CD34+ cells 
CD34 is a transmembrane phosphoglycoprotein that was discovered on HSC in 1984 
(199). Expression of CD34 on hematopoietic progenitors (CD34+ cells) is used to evaluate 
engraftment in BMTs (200). CD34+ compose a small fraction of cells in the bone marrow; they 
are found at a frequency of 1- 4% (201). CD34+ HSCs have a high proliferative ability and can 
differentiate into all cell types of hematopoietic lineages, including erythroid cells (202). CD34+ 
cells were not able to be used in research until a method for collecting them was developed in 
1988 (203). There remain drawbacks to their use because CD34+ cells are difficult to isolate in 
large quantities and cannot be kept in culture for long (202) (204). Despite these difficulties, 
CD34+ cells continue to be widely used for research as they are the most accurate human cell 
model available.  
For example, CD34+ cells have been an important tool for developing new methods of 




Chapter 2.3.a, in vitro studies performed in 2015 used lentiviruses to target either the - or -
globin gene to increase expression of HbF or inhibit HbS. This study showed transduction of 
cells from SCD patients with these lentiviruses resulted in healthy cells that had increased levels 
of HbF, reduced HbS, and therefore reduced sickling of RBCs (205). In 2016 two different 
groups implemented CRISPR/Cas9 technology as a tool for treating SCA. One group was 
successfully able to target and correct the point mutation in the β-globin gene of SCA patient 
cells which resulted in production of normal hemoglobin in culture (206). The other group used 
CRISPR/Cas9 to introduce HPFH variants that resulted in an increase in HbF in culture (207). 
CD34+ cells have also contributed to the understanding that BCL11A is a transcriptional 
repressor of the -globin gene. A 2011 study found lentivirus infection containing either the -
globin gene, a transcription factor designed to interact with the -globin promoter, or a shRNA 
targeting BCL11A were all able to increase HbF in CD34+ cells taken from -thalassemia 
patients (208). Another study done in 2017 used zinc finger nucleases to make a targeted 
disruption of the GATA motif in the BCL11A gene of SCA cells. This study showed an increase 
in HbF and the production of hematopoietic stem and progenitor cells (HSPCs) that are capable 
of long-term engraftment (209). These developments are important to the field because, as 
mentioned in Chapter 1, methods for gene therapy of the β-hemoglobinopathies are lacking. 
These studies are a step towards developing autologous gene therapy treatments for patients. 
3. Transgenic Mice 
Mouse models have long been used to study the mechanisms associated with disease and 
as models to test treatments. The physiologic similarity mice have to humans is why mice were 
originally chosen and continue to be used as a model system. Transgenic mice are mice that have 




method is by microinjecting recombinant DNA into the pronuclei of fertilized eggs (210). This 
method allows for almost any sequence of DNA to be introduced into mice which is then 
integrated into their genome. This provides the possibility to study any disease and phenotype 
desired, with focus on studying globin gene switching and erythropoiesis. The major drawback 
of earlier studies was that individual genes rather than the entire β-globin locus was inserted 
(211). In 1987 yeast artificial chromosome (YAC) libraries were created, which allow for large 
segments of DNA to be cloned into yeast (212). With this discovery came the possibility of 
being able to insert even larger segments of DNA into mice, including the entire β-globin locus.  
This led to the creation of YAC mice, which provided researchers with a better model 
for studying globin gene switching and β-hemoglobinopathies (213) (214). As discussed in 
Chapter 2, the human globin genes are expressed in a particular order, with a major switch 
occurring at birth when the -globin gene is silenced and the β-globin gene begins to be 
expressed. Like humans, mice express all genes in the order in which the genes are arranged. The 
difference is mice do not have a -globin gene and switch to expression of -globin in the fetal 
liver, which means their switch to adult globin occurs earlier than in humans (215) (216) (217). 
This is a problem with the YAC transgenic model because the expression of the globin genes 
does not occur with the same timing as in humans (215). Despite this drawback, YAC 
transgenic mice are still a good model for studying hemoglobin and remain to be used often. 
They have contributed to the extensive studies of human hemoglobin switching, as hemoglobin 
switching and development can only be studied in animal models (218) (213) (219).  
Studies using transgenic mice have contributed to the study of the LCR (discussed in 
Chapter 1.2.c) (220) (221) (215). Understanding how the LCR functions is important because it 




have also been used to study HPFH, sickle cell anemia, β-thalassemia, and the transcription 
factors discussed in Chapter 2. The discoveries made in these studies have contributed to the 










a. Gap #1: What is the association between KLF1 and chromatin looping?   
The role of KLF1 in maintaining chromatin conformation was discussed in Chapter 2.2.b. 
However, it is still not completely understood how KLF1 affects chromatin, and thereby globin 
gene expression. It remains unknown how many of the interactions KLF1 has are important for 
chromatin looping and how chromatin accessibility changes throughout the process of 
differentiation. 
A paper published in 2010 performed a ChIP-seq study in mouse E14.5 fetal livers and 
presented the finding that KLF1 occupies 945 sites in erythroid cells (222). They saw many of 
these sites are in erythroid gene promoters, but most of the binding sites are at distances of 10 kb 
or more from a transcription start site (TSS) of any known gene. They hypothesize these distal 
KLF1 binding sites could be promoting chromatin looping to interact with the gene promoter or 
that these sites are novel erythroid-specific gene promoters (222) (223). In 2018 a study 
performed by a different group paired RNA-seq and ATAC-seq using HSPCs to analyze genes 
implicated throughout erythropoietic differentiation (224). Their analysis found chromatin 
accessibility at the KLF1 locus increases throughout terminal differentiation. This is associated 
with an increase in expression of its target genes. These findings suggest KLF1 is more active 
during the later stages of erythropoiesis. This finding is interesting because it sheds light on the 
chromatin conformation of KLF1 at different points during erythropoiesis and how this likely 




both of these studies are important for understanding KLF1, they still leave the question of how 
KLF1 is changing chromatin conformation to promote interactions. The role KLF1 plays at many 
of the identified binding sites is unknown. Could these sites be important for the promotion of 
chromatin looping and formation of the ACH? Chromatin Conformation Capture (3C) is a 
technique that analyzes the spatial organization of DNA regulatory elements and the target gene 
in a specific region or of the whole genome in order to provide information on 3D chromatin 
structure (225). 3C works by performing proximity ligation, which uses formaldehyde to 
crosslink proteins and DNA that are interacting. The cross-linked DNA is then digested with 
restriction enzymes and qPCR is performed to identify and quantify the products, as well as to 
determine spatial proximity of the linked chromatin (226) (227). To know if chromatin looping is 
occurring at any of these sites, but particularly within the -globin locus, with KLF1 binding at 
these sites a 3C technique could be used.  
b. Gap #2: Does the binding of KLF1 to the -globin promoter change from embryonic to 
adult stage, and how can this be better studied in a human erythroid cell system? 
The evidence supporting the role of KLF1 in indirectly repressing -globin gene 
expression in adults is strong. In Chapter 2.2.b and 2.3.b it is discussed how KLF1 works to 
repress -globin gene expression in adults indirectly through its interaction with BCL11A (153) 
(154). KLF1 null embryos are not viable because the switch from embryonic to adult globin is 
blocked (123) (135). The question that remains is if KLF1 positively regulates embryonic and/or 
fetal globin expression in fetal erythroid cells. This topic has been studied well, but the majority 
of the studies have been performed in YAC transgenic mice and not in human erythroid cells. 




interactions KLF1 has with the different -globin locus genes at the different stages of 
development.  
A study performed using human YAC transgenic mice showed KLF1 positively 
regulates -globin expression in embryonic and fetal erythroid cells (128). This study also found 
KLF1 binds directly to the human - and -globin gene promoters as well as the -globin LCR, 
suggesting that KLF1 is positively regulating these genes directly through its interactions with 
the promoters. This study provides evidence that KLF1 is not needed only for the - to -globin 
gene switch but also promotes gene expression during the embryonic to fetal switch. Other 
studies had shown KLF1 has many roles during primitive and definitive erythropoiesis, including 
its role in the - to -globin switch (228) (124) (229). One study in CD34 UCB derived 
erythroblasts that represent the fetal environment saw significant KLF1 binding at the -globin 
promoter and detected some binding at the -globin promoter (230). Additionally, there have 
been mouse studies that show a decrease in -globin expression during the embryonic stage in 
KLF1 knockouts (128) (231). This provides more evidence that KLF1 is involved in regulating 
embryonic and fetal gene expression.  
In all but one of the studies discussed in the previous paragraph the model system used 
was YAC transgenic mice; the single study used CD34+ cells. The studies in YAC transgenic 
mice support the role of KLF1 binding to embryonic and fetal globin promoters during 
erythropoiesis. The study in CD34+ cells does as well but their evidence is not as strong as they 
only saw low levels of binding. It is known KLF1 is expressed throughout erythropoiesis during 
the embryonic and fetal stages from the research mentioned above. It is also established that in 




it is interacting with the - and -globin promoters in human cells lines needs further 
investigation. There is the possibility that differences in the model systems used could result in 
an improper understanding about when KLF1 is regulating embryonic and fetal globin during 
development. To address this issue more studies could be conducted in human cell systems. 
Using human cells systems has a drawback that none behave as an embryonic/fetal system and 
then switch to an adult system. Despite this drawback, it could be worth investigating this role in 
HUDEP cells. HUDEP-1 cells could be a useful tool for studying this. These cells are similar to 
HUDEP-2 cells (discussed in detail in Chapter 3.4), but they differ in that HUDEP-1 cells 
express predominantly -globin after differentiation instead of -globin like HUDEP-2 cells 
(194). Studies could be done in the HUDEP-1 cell line to see if KLF1 is binding to the -globin 
promoter before and after differentiation to determine if KLF1 is regulating the -globin gene in 
human derived cells. This could potentially be done in HUDEP-2 cells as well. Since they can be 
manipulated to express -globin it is possible the interaction of KLF1 at the -globin promoter 
could then be studied. A gene that represses -globin expression, like MBD2, could be knocked 
out to restore the expression of the -globin gene. Then it can be investigated to see if KLF1 is 
binding to the promoter of the -globin gene. These two studies could potentially show if KLF1 
is regulating the -globin gene in human derived cells. Performing this study would still leave a 
gap in the understanding of how KLF1 is binding the -globin gene, as there are no good human 






c. Gap #3: Why are some KLF1 variants detrimental and others benign/beneficial? Is it 
related to how the variant affects KLF1 DNA binding? 
As discussed in Chapter 2.2.b, there are many diseases and disorders caused by variants 
in the KLF1 gene. Interestingly, some KLF1 variants rescue -thalassemia phenotypes. Different 
KLF1 variants have been found in individuals who should have -thalassemia based on their 
genotypes, but have very mild to no dependence on blood transfusions (232) (65). This suggests 
that these KLF1 variants increase HbF enough to ameliorate the effects of -thalassemia. The 
differences in the phenotypes caused by KLF1 variants raises the question of why some cause 
detrimental diseases while others are beneficial? The answer to this question could be found by 
analyzing where each of the variants is located within the KLF1 gene. This analysis will focus on 
the thalassemias and HPFH. Detailed descriptions of these and other KLF1 disorders can be 
found in Chapters 1.2.d and 2.2.b 
- and -thalassemia were discussed in detail in Chapter 1.3.b and the mechanism by 
which loss of binding of KLF1 to the -globin gene can cause -thalassemia was discussed in 
Chapter 2.2.b. The loss of KLF1 binding to the -globin gene can cause -thalassemia because it 
can no longer activate -globin gene expression (123). It was also discussed in Chapter 2.2.b 
how mutations of the -globin gene CACCC element can result in loss of KLF1 binding. There 
are four known mutations in the CACCC box that cause -thalassemia. Two mutations, 
identified in 1982, are a C to T transition at position -87 or -88 of the proximal CACCC box 
(233) (192) (234). In 1989 a C to T transition was also found at position -101 in the distal 
CACCC element (235) (236). In 2004 a fourth mutation, a C to G transition at position -101, was 




still important to mention because they affect the function of KLF1 at the -globin gene. These 
mutations prevent the KLF1 zinc fingers from being able to recognize and bind to the CACCC 
elements, which results in -thalassemia because KLF1 is no longer promoting expression of the 
-globin gene.  
KLF1 mutations can also cause -thalassemia; there is a report of a KLF1 null human 
with hydrops fetalis, a form of -thalassemia, who was able to survive past birth (238). It was 
found this individual is compound heterozygous for KLF1 null mutations: W30X and 
R319EfsX34. These genes were inherited from asymptomatic parents. The R319EfsX34 
mutation is a result of a frameshift in exon 3 and the W30X mutation occurs in exon 2 and is a 
novel finding. RNA-seq indicated no functional protein is made from the W30X allele. The 
R319EfsX34 mutation results in a truncated protein that also is not functional. It is surprising 
that a KLF1 null human can survive past birth with no functional protein given that KLF1 null 
mice is lethal in utero. It is speculated that no other cases have been seen before because they are 
lost in utero and it is not realized the loss is due to KLF1 deficiency. It would be interesting to 
know if these mutations are occurring in cases of fetal loss because they could account for cases 
of fetal loss that are currently not explained. 
In individuals with -thalassemia, KLF1 variants that increase HbF are also sometimes 
found. A study performed in 2014 that had a population of 1,190 individuals from northern 
China, where thalassemia is not common, and 3,839 individuals from southern China, where 
thalassemia occurs often, identified KLF1 variants in 1.25% of the population from southern 
China and only 0.08% of the population from northern China. Their findings indicate KLF1 
variants occur at a significantly higher prevalence in an area where thalassemia is endemic 




where an individual’s genotype indicates they should have -thalassemia, but they do not present 
any phenotypic symptoms. Upon investigation, it was found these individuals have KLF1 
variants that increase their HbF levels seemingly ameliorating their symptoms. This study also 
identified three novel variants in 12 -thalassemia patients with increased HbF; one is a missense 
variant in exon 2 and disrupts zinc finger 1, one is a missense variant in exon 3 and disrupts zinc 
finger 3, and the third is another missense variant in exon 1 that is located in the proline rich 
TAD (232). It is interesting to note that this final variant is not located in the DNA binding 
domain like the other variants. Its location in the TAD could disrupt the interaction of KLF1 with 
other proteins. If this is the case it could be an explanation for the phenotype. Another study 
identified a novel variant, p.Ser323Leu, in two brothers that have the IVS1‐110; HBB: c.93–21 
G > A mutation indicating they should exhibit severe -thalassemia, but instead they are fine and 
do not need any transfusions. The KLF1 variant is a missense variant in exon 2 and zinc finger 2 
(65). This study performed in silico structural analyses of the zinc finger 2 and found the serine 
at position 323 is pointed towards the DNA. The substitution of leucine does not alter the 
structure of the zinc finger but increases the distance of residue 323 from the DNA backbone. 
This is suggested by the fact that serine is polar and hydrophilic, while leucine is nonpolar and 
hydrophobic; this change from a polar to a nonpolar residue could affect the formation of 
hydrogen bonds that are important for the stability of KLF1 binding.  
At least fifteen additional different variants have been identified in KLF1 by investigating 
variants that cause HPFH. A study performed in 2012 on 131 individuals with HPFH identified 
KLF1 variants in 8.4% of their subjects (239). Not all of the identified HPFH variants will be 
discussed here, but instead the focus will be on the most common ones, a KLF1 promoter 




individuals of African, Indian, and Southeast Asian descent. One of the more commonly reported 
variants is the nonsense variant p.K288X located in exon 2 that ablates the zinc finger domain 
and therefore DNA binding (58). Another variant that is more commonly reported is the 
nonsense variant S270X located in exon 2. This variant is also predicted to eliminate KLF1 
interaction with DNA by ablating the zinc finger domain. Unlike those with the p.K228X 
variant, individuals with the S270X variant are compound heterozygotes who also have a K332Q 
missense variant in exon 3 in zinc finger 2, with the two variants in trans (66). One last variant 
that has been seen in multiple studies is the frameshift variant G176AfsX179 in exon 2. This 
variant is the result of a 7 bp insertion that produces a premature stop codon (239) (240). The 
location of this variant in exon 2 before the zinc fingers likely explains why this variant causes 
HPFH – KLF1 will not have binding function. This study identified eight other missense variants 
with one located in exon 1 and the others distributed within the zinc fingers. The final variant 
they identified is another frameshift variant that occurs in exon 2 due to an 11 bp deletion that 
results in a premature stop codon (239). A different frameshift mutation as a result of a 4 bp 
insertion in exon 2 has also been identified (240). The final variant that will be discussed here is 
the g.-148G>A variant in the promoter of the KLF1 gene, which is the first variant to have been 
identified in the promoter of KLF1 (67). In silico analysis performed in this study predicts the 
variant occurs in a Sp1 binding site. It is predicted the loss of this binding site for Sp1 decreases 
transcription of the KLF1 gene. 
What causes some KLF1 variants to be detrimental and some to be beneficial? Looking at 
the data presented above the noticeable difference between variants that cause thalassemia and 
HPFH is that the variants in individuals with thalassemia result in no interaction with or 




functional KLF1. This can be explained by the finding from a separate study that shows when 
KLF1 is knocked down in CD34+ cells by more than 70% there is not a significant increase in 
HbF but when it is knocked down in the range of 40-70% an increase in HbF is seen (230). This 
shows there is a threshold amount of KLF1 needed to see the beneficial effects of the knockdown 
of KLF1.  
Looking at the variants causing HPFH the only noticeable pattern is a lot of the variants 
occur within or between the three zinc fingers (Figure 8), even though the zinc fingers only make 
up about 20% of KLF1 (241). Zinc fingers are small but important for the interaction of KLF1 
with DNA as they are what recognize and bind CACCC elements. It makes sense that disruption 
in these domains results in a phenotype because KLF1 is no longer able to bind to other genes to 
regulate them. It is also not surprising that there only needs to be a variant in one of the three 
zinc fingers in order to see a phenotype because KLF1 needs all three of the zinc fingers for 
proper binding (242). This can also explain why there does not seem to be one zinc finger that 
variants occur in more often than others. Other commonalities among the HPFH variants are: 
over half of the variants seen are due to missense variants, and the majority of variants occur in 
exons 2 or 3 – only 2 variants were seen in exon 1. This disparity is likely because exon 1 is very 
small and exon 2 is the largest. Some of these studies looked into the mechanism by which the 
variants cause their phenotypes, but most did not. Of the studies that did investigate the 
mechanism of the variant, most of them provided evidence that the variations they found have an 
effect because they ablate binding by the zinc fingers. The loss of zinc finger binding would 
result in a HPFH phenotype because KLF1 cannot bind to the -globin gene to promote its 




reduction in expression of -globin and a decrease in repression of -globin would result in an 
increase in the HbF percentage.  
To better understand how these variants cause HPFH it would be beneficial to investigate 
the mechanism of function of every variant. It is understood the variants in the zinc fingers cause 
HPFH because they reduce KLF1 DNA binding efficiency. More investigation of these variants 
could reveal there is a change in the DNA sequence recognized by some KLF1 variants, like 
what is seen in the Nan mutant mouse model. The Nan mouse is a model for neonatal anemia; 
homozygotes die at E10 due to a severe lack of hemopoiesis and heterozygotes survive but have 
severe hemolytic anemia throughout their life (231). The causal mutation for this has been found 
to be a single missense mutation E339D in the second zinc finger of KLF1 (231) (243). This 
mutation is similar to the human mutation E325K that causes CDA IV (discussed in Chapter 
2.1.b), which has a similar phenotype to the Nan mouse model (231) (244) (245). This Nan 
mutation causes KLF1 to bind to its target sequences with less affinity and changes the 
specificity of its binding from what is seen in WT or KLF1 null RBCs (231). This finding 
introduces the idea that this could also be happening in the case of some of the variants discussed 
here. More studies need to be done to uncover if this is the case. 
It would also be useful to understand how the variants outside of the zinc fingers result in 
a phenotype. Many of the variants outside of the zinc fingers are frameshift variants that result in 
a truncated protein that is lacking the zinc fingers, which has the same result as a mutation in the 
zinc fingers. But what about the missense variant in exon 1, or the variant in the TAD, or the 
variant in the promoter? What interactions could KLF1 be losing because of the variant in the 
TAD? And how does the missense variant in exon 1 cause HPFH? Does it cause protein 




could provide researchers with an understanding as to why some variants cause HPFH and some 
do not. Another factor that would help clarify this difference would be to know more about 
KLF1 variants that do not cause any disorder. The UCSC Genome Browser 
(https://genome.ucsc.edu/) compiles reported KLF1 variants, but for the majority of the variants 
the functional consequence is not available. If the phenotype of each KLF1 variant was reported 
the location of those variants within KLF1 could be compared to disease causing mutations. 
Comparing these variants to disease causing mutations could help uncover critical regions or 




What interactions does BCL11A have that influence its repressive function on the -globin 
gene? 
When a GWAS identified BCL11A as a repressor of -globin expression in 2008 (64) it 
introduced the question of how or if BCL11A binds to and interacts with the -globin gene to 
repress it. The details of this GWAS were presented in Chapter 2.3.a. The literature has provided 
conflicting evidence about whether BCL11A acts on the -globin gene at its promoter or at a 
Figure 8: KLF1 Locus with Mutations Clustered in the Zinc Fingers 
Depiction of the KLF1 locus with the location of some of the mutations discussed in this chapter 
indicated. Mutations are indicated by white circles. Most of the mutations are located in the zinc 
fingers. Grey boxes = zinc fingers. White boxes = exons. Black boxes = introns. Hatched = 




distance. The most recent studies provide compelling evidence that BCL11A is binding at sites 
in both of these locations. 
The first theories about how BCL11A binding represses the -globin gene proposed 
BCL11A acts outside the -globin promoter but within the -globin gene cluster. This theory 
arose because ChIP experiments showed binding at HS 3 of the LCR and between the - and -
globin genes (246) (247). This introduced the idea that BCL11A acts from a distance. To test 
this, a 3C assay was performed. The study used mouse fetal liver cells derived from YAC mice 
that were either WT or null for BCL11A. The study used the LCR as their anchor location and 
found that in the WT mouse cells the LCR had the highest cross-linking efficiency with the -
globin gene; in the null cells the -globin gene has a high cross-linking efficiency with the LCR. 
They also used the 3’HS and saw the same results. The proposed mechanism that came from this 
was BCL11A binds to these distal control regions – the LCR HS3 and in between  and  – and 
reconfigures the -globin locus by modifying chromosomal looping to allow for the LCR and the 
3’HS elements to interact with the -globin gene; when BCL11A is not present the chromosomal 
looping changes so that the LCR and the 3’HS elements favor interaction with the -globin gene 
(247).  
Studies were performed to determine if chromatin occupancy of BCL11A coincides with 
common histone modifications – H3K9ac, H3K4me2, H3K4me3, and H3K27me3 (247). A 
ChIP-Chip experiment using CD34+ WT cells was performed and it was observed that there 
were peaks of H3K9ac, H3K4me2, and H3K4me3 upstream of the LCR, at the - and -globin 
genes, and in the - -globin intergenic region; weak peaks of the active histone modifications 




the -globin genes. These findings are to be expected because H3K9ac, H3K4me2, and 
H3K4me3 are associated with transcriptionally active genes, while H3K27me3 is associated with 
transcriptional repression and the locations at which peaks of these histone modifications are 
seen agree with the gene expression that should be seen. With the establishment of the location 
of the histone modification peaks, they then looked at the peaks where BCL11A binds in the -
globin gene locus and saw there is very little overlap between BCL11A binding sites and peaks 
of the histone modifications mentioned above. Even at HS 3 upstream of the LCR and in the - 
-globin intergenic region where it is thought BCL11A binds and histone modification peaks 
were seen, the sites where BCL11A binds happen to be in between the peaks where the histone 
modifications occur. Another study looked to see how knockdown of BCL11A affects the 
histone marks (248). They saw that with knockdown of BCL11A the histone mark H3K4me2 – 
which is associated with active transcription – is increased at the -globin promoter and in the - 
-globin intergenic region. Additionally, both of these studies saw an increase of RNA 
polymerase II at these regions as a result of the loss of BCL11A, which promotes transcription. It 
is not known why there is a lack of the histone modifications discussed above at BCL11A 
binding sites. Some theories are: once BCL11A binds it blocks the nucleosomes from histone 
modifications, that the sites BCL11A binds possess specific chromatin features that protect them 
from histone modifications, or simply that BCL11A binds to nucleosome free regions (247). It is 
possible this feature of BCL11A is what enables its repressive function. Further experiments 
need to be done in order to answer these questions.  
Additional studies into how BCL11A represses the -globin gene led to findings that it 
binds with many other regulatory factors. One study performed a survey in human primary 




GATA1 (157). This interaction will be discussed in the next paragraph. Another study performed 
a knockdown of BCL11A in adult erythroid cells and saw a subsequent reduction of HDAC1, 
particularly in the region between the - and -globin genes (156). This suggests that BCL11A 
recruits HDAC1 to this region to establish repressive chromatin modifications, so when BCL11A 
is knocked down HDAC1 is no longer recruited to this site which results in less repression of the 
-globin gene. A different study affinity tagged BCL11A in MEL cells and performed mass 
spectrometric peptide sequencing. They identified a strong association between BCL11A and the 
NuRD complex (246). The relationship between BCL11A and the NuRD complex will be 
discussed in the following paragraph. Another study performed gel filtration chromatography on 
CD34+ nuclear extracts and saw a comigration of SOX6 with BCL11A. They also performed a 
co-IP and saw BCL11A coimmunoprecipitates SOX6 (247). One final study performed a 
proteomic screen in MEL cells to identify multiprotein complexes that contain BCL11A. They 
identified interactions with all of the previously mentioned proteins, as well as interactions with 
IKAROS, SWI/SNF, LSD1/CoREST, NCoR/SMRT, BCOR, and DNMT1 (248). The interaction 
of BCL11A with these proteins was identified using liquid chromatography tandem mass 
spectrometry (LC-MS/MS). The copurified proteins were extracted from SDS/PAGE and then 
used to perform LC-MS/MS. LC-MS/MS is a technique that first uses LC to separate peptides 
based on their hydrophobicity, then the eluted peptides are passed through the MS/MS and are 
detected based on their mass-to-charge ratio (249). Based on the data generated for the peptides 
eluted it can be determined which proteins interact with BCL11A. All of these identified 
interactions with BCL11A led into the second proposed mechanism that BCL11A acts at the 




and transcriptional repressors in order to repress the -globin gene from a distance (157) (156) 
(248).  
It is speculated that BCL11A repressive function on the -globin gene is dependent on its 
formation of multiprotein complexes made up of chromatin modifying agents and transcriptional 
repressors. There have been many studies reporting its interactions with multiple different 
proteins (246) (247) (157) (156) (248); one of these reported interactions is with GATA1/FOG1 
(246) (157). GATA1 and FOG1 were discussed in detail in Chapter 2.2.a. The first study showed 
via immunoprecipitation (IP) that BCL11A and GATA1/FOG1 bind to each other in MEL 
erythroid cells. They propose that since FOG1 binds to the NuRD complex (109) then the 
interaction of BCL11A with GATA1/FOG1 suggests BCL11A may interact with NuRD as well. 
This study supported their idea by performing size fractionations on MEL nuclear extracts. They 
saw overlap between NuRD and BCL11A (246). It is interesting to note the observed connection 
between BCL11A and the NuRD complex. Since this interaction was first shown in 2008 (246) it 
has been modified due to new findings. The finding in the 2008 study was identified using 
MBD3-NuRD. It has since been found that MBD2-NuRD is important for repressing the -
globin gene, not MBD3-NuRD (250) (168). Researchers now believe BCL11A is not interacting 
with MBD3-NuRD but that it does interact with MBD2-NuRD, though there is no direct 
evidence to support this. The available evidence shows that disruption of MBD2-NuRD, but not 
MBD3-NuRD, increases -globin expression, supporting the idea that BCL11A interacts with 
MBD2-NuRD and not MBD3-NuRD.The second study performed a survey of BCL11A and 
GATA1 binding in human erythroid K562 cells by using microarray-based chromatin IP (ChIP-
Chip) studies, which identifies protein-DNA interactions in vivo, in order to better understand 




BCL11A and GATA1/FOG1. They investigated the binding at the BCL11A and GATA1 genes 
individually. They looked at the BCL11A gene and saw GATA1 binding at the promoter of 
BCL11A as well as in intron 2, which has conserved GATA1 binding motifs. They then looked 
at the GATA1 gene and saw binding of BCL11A at a positive auto-regulatory promoter of the 
GATA1 gene (157).  
Another demonstrated interaction of BCL11A is with SOX6, which also generates the 
theory for how BCL11A promotes chromatin looping. SOX6 is a member of the Sry-related 
high-mobility group (HMG) box transcription factors. This interaction was identified by gel 
filtration chromatography of human erythroid nuclear extracts, which show BCL11A and SOX6 
comigrate. Then, a co-IP was done with epitope-tagged proteins expressed in COS7 cells to 
determine where BCL11A and SOX6 are interacting. It was found the C-terminal of BCL11A, 
amino acids 732 – 835, contains three zinc fingers sufficient for SOX6 binding. Additionally, the 
first 90 amino acids of the N terminal have been found to be important for SOX6 binding. ChIP-
chip has shown some overlap between BCL11A and SOX6 at the HS 3 site upstream of the LCR. 
It also showed SOX6 binds the -globin proximal promoters but BCL11A does not (247). This 
all shows BCL11A and SOX6 interact to repress -globin expression. It is proposed this 
interaction is what allows for chromatin looping to bring BCL11A to the -globin promoter. 
SOX6 contains a HMG domain that binds to the minor groove of DNA and induces drastic DNA 
bending, which allows for long-range enhancers to function on the DNA by bridging these 
distant regions (251) (252) (253) (247). When SOX6 is bound at the -globin promoter it could 
induce this chromatin bending to loop to then interact with BCL11A that is bound at the 5’HS 3. 
Or when BCL11A and SOX6 are both bound at the 5’HS 3 SOX6 could promote chromatin 




More recently, a DNA sequence to which BCL11A binds and a new method for how it 
represses the -globin gene have been proposed. Two separate 2018 studies identified that 
BCL11A binds the TGACC sequence and they each adapt some of the aspects of the previous 
studies to form their theory. The first study identified this sequence by performing the universal 
protein-binding microarray (PBM) platform (155). They verified these findings using 
CUT&RUN – a method that maps protein binding sites and their long-range genomic 
interactions – in HUDEP-2 and CD34+ cells. Of the 12 motifs in the locus the ones within the -
globin promoter were predicted to have the highest binding probability. Analyses of these motifs 
revealed BCL11A prefers binding the distal TGACCA motif from nucleotides -118 to -113 in the 
-globin promoter. To prove BCL11A is binding this distal TGACCA motif, they created a 
HUDEP-2 cell line where the distal motifs of the -globin promoters were mutated. qRT-PCR 
showed these cells had a /(+) ratio of 77%, compared to less than 1% in WT cells, and 3C 
showed a switch in interaction from the LCR at the -globin gene to the LCR at the -globin 
gene. The second study identified this binding site by using an epitope tag system that contains a 
tamoxifen-responsive estrogen receptor moiety (ER) and a V5 tag. They used CRISPR-Cas9 to 
introduce this onto the C terminus of BCL11A in HUDEP-2 cells. They then performed ChIP-
qPCR and ChIP-seq. They identified a peak at -115 bp which the TGACC site encompasses and 
which agrees with the other study’s findings (254). The first study uses this evidence to adapt the 
chromosomal looping theory to propose the binding of BCL11A at this distal motif in the -
globin promoter prevents a stable loop from being able to be formed and shifts the interaction of 
the LCR to the -globin gene to promote its expression, and that when BCL11A is not bound to 
this motif chromosomal looping is able to occur in a way that allows for the LCR to bind to the 




theory for how they think BCL11A is functioning from this site, but they do propose that 
because they see BCL11A peaks in regions that do not contain TGACC motifs, BCL11A could 
be acting at these distal regions to promote chromatin looping as well as at the motif in the -
globin promoter in order to repress its expression (254). These are the most recent theories and 
are the first to give definitive evidence of a sequence BCL11A binds, but it is still unclear as to if 
this is the actual mechanism by which BCL11A functions to repress -globin expression. The 
binding of BCL11A at the -115 site could inhibit transcription of the -globin gene because its 
presence there interferes with the ability of LDB1 to form a stable complex at the -globin 
promoter. This could weaken the ability of LDB1 to promote chromatin looping of the LCR to 
stably complex with the -globin promoter, or it could prevent LDB1 from promoting chromatin 
looping with the LCR at the -globin promoter altogether. These studies also saw TGACCA 
motifs in between the  and  genes and at the LCR. These are the sites at which the previous 
studies showed BCL11A binds to the DNA, which could explain why the previous studies 
identified these regions.  
Findings from these more recent studies could provide a framework to unify the theories 
generated from the earlier studies. BCL11A could be acting at multiple sites at once. If BCL11A 
binds at all of the proposed sites, then each of these studies has presented only a piece of the 
mechanism by which BCL11A represses -globin. The more recent studies present evidence of 
BCL11A binding at TGACCA motifs. Binding peaks are observed in between the  and  genes 
and at the LCR, in addition to the strong binding at the -115 motif in the -globin promoter (155) 
(254). This suggests that all of the theories discussed in the studies presented here have a piece of 
the mechanism correct, and together form a more complete description of the mechanism by 




distal promoter of -globin where it interacts with SOX6 (247), as discussed above, to promote 
chromatin looping. This chromatin looping brings the BCL11A that is bound to the HS3 at the 
LCR into proximity of the -globin locus. The way that BCL11A causes chromatin looping is a 
function that needs to be studied further. The best theory presented this far is its interaction with 
SOX6. BCL11A could be interacting with any number of the other proteins discussed in this 




How does MBD2 repress -globin gene expression? If it is not binding the gene directly, 
what proteins is MBD2 interacting with to exert its repressive function? 
MBD2 typically binds to methylated CpG rich regions and recruits the NuRD complex to 
help regulate gene expression (162) (167). It is well established that MBD2 represses the -
Figure 9: Proposed Mechanism of BCL11A Binding 
Top: when BCL11A is present it binds to the TGACCA sequence and prevents the LCR from being 
able to loop and bind to the -globin gene; the LCR instead loops and binds at the -globin gene. 
When BCL11A is not bound at the TGACCA sequence the LCR is able to loop and bind to the -




globin gene because when it is ablated, expression of -globin increases (165) (168). However, 
there are no CpG islands within 6 kb of the -globin gene (165). Thus, despite knowing MBD2 
represses the -globin gene, the mechanisms by which it works are still unknown. If MBD2 is 
not binding at the -globin promoter via a CpG island, then it must have other interactions with 
proteins or transcription factors, or other functions that allow it to exert its repressive effects on 
the -globin gene.       
There have been a number of proposed interactions provided to explain how MBD2 binds 
the -globin gene in order to repress it. One interaction is the MBD2 coiled-coil domain with 
p66. p66 is a component of the NuRD complex that is responsible for the association of 
MBD2 with the NuRD complex. Forced expression of the p66 coiled-coil domain in CID -
YAC bone marrow progenitor cells or MEL cells reverses MBD2 silencing of the -globin gene 
(171). This indicates the repressive function of MBD2 is dependent, at least in part, on its 
binding to the p66 coiled-coil domain. An explanation for how forced interaction of the p66 
coiled-coil domain with MBD2 results in loss of transcriptional repression is that this interaction 
blocks MBD2 from binding to the NuRD complex (171).  
MBD2 also interacts with CHD4. CHD4 is a member of the NuRD complex, and a study 
of how CHD4 functions to bring the NuRD complex to the B-cell-specific gene mb-1 (Cd79a) 
found CHD4 is responsible for performing the chromatin remodeling activities of NuRD (255). It 
found MBD2 binding of CHD4 is necessary for silencing of the gene. Additionally, they found 
certain CHD4 mutations result in reduced function of the NuRD complex, preventing it from 
binding MBD2 and from exerting its repressive function (255). This association was shown in a 




interaction with the NuRD complex. Another study found CHD4 is important for the function of 
MBD2 at the -globin gene because when enforced expression of the p66 coiled-coil domain is 
introduced it competitively binds to MBD2, which prevents the recruitment of CHD4 and p66 
to the MBD2-NuRD complex (171). The disruption of these interactions results in an increase in 
-globin expression, which indicates both p66 and CHD4 are required for MBD2 repressive 
activity.  
Another feature of MBD2 that is important for repression of the -globin is the IDR of 
MBD2. The IDR is required for MBD2 to recruit the HDCC of NuRD, which contains MTA2, 
HDAC2, and RbAp48. A study performed in 293T cells identified two important locations in the 
MBD2-IDR that are critical for its binding of this complex. Point mutations of these two residues 
weaken the interaction of MBD2 with the HDCC (170). Forced expression of these two MBD2-
IDR mutants in HUDEP-2 cells that lack MBD2 results in failure of MBD2 to repress -globin 
expression (168). It is thought these mutations cause this result because they disrupt the structure 
of the IDR which affects its ability to bind to the HDCC.  
The evaluations of each of these interactions individually indicates MBD2 requires 
NuRD to repress the -globin gene. Two of the interactions MBD2 needs to bring it in contact 
with NuRD are between its coiled-coil and its IDR domain with different components of the 
NuRD complex. To see if these domains are necessary for the repressive function of MBD2 on 
the -globin gene, forced expression of WT MBD2, a coiled-coil mutant, or an IDR mutant in 
MBD2 knockout HUDEP-2 cells was performed. The addback of WT MBD2 showed a 
significant reduction in expression of the -globin gene compared to control, rescuing the 




phenotype; they failed to repress the -globin gene (168). These results show MBD2 needs these 
domains to function and that both need to be functional for MBD2 to repress -globin 
transcription. If MBD2 needed only one functional domain to repress -globin gene expression 
then abolishing the function of one of the domains would not affect its repressive activity, but 
that is not the case.  
These mechanisms were suggested under the assumption that MBD2 was binding to 
methylated CpG rich regions, but it is now believed that there are no CpG islands in the -globin 
locus. A CpG island is a cluster of CpGs in GC rich regions of the genome (256); they are about 
1,000 bp long and have a GC content greater than 50% (257) (256). About 70% of gene 
promoters are associated with a CpG island, which is important for gene expression (258) (257). 
When CpGs are methylated; when they become methylated proteins, MBD2 can recognize the 
site and bind it, resulting in silencing of the associated gene (256) (257) (259) (260). All of these 
proposed mechanisms can still be valid for how MBD2 is functioning to silence the -globin 
gene, but there must be some other factor involved that allows MBD2 to bind to methylated but 
CpG-poor regions of the -globin locus. It could be that there is another protein that binds to the 
-globin gene and then to MBD2 to anchor it there. Or, it could be that there is a region of 
MBD2 yet to be studied that gives it the ability to bind to CpG-poor DNA. 
MBD2 could be binding to the -globin gene through an interaction with BCL11A. As 
discussed in the previous section, it is believed BCL11A and NuRD interact. It is thought 
BCL11A interacts with the NuRD complex through RbAp48 and RbAp46 and through this 
interaction BCL11A is able to interact with other members of the NuRD complex, like CHD4 




interactions through CHD4 brings them together. The interaction of MBD2 with CHD4 could be 
bringing it to where BCL11A is bound on the -globin gene and then MBD2 could bind with 
BCL11A to repress the gene. This is one possible explanation for how MBD2 could bind the -
globin gene without methylated CpG islands. Another explanation could be MBD2 does not need 
to bind to other factors in order to repress the -globin gene because it has a region that allows it 
to bind to CpG-poor DNA. MBD2 can bind to CpG-poor DNA (262), but it is still unknown how 
it does this and how it represses transcription from an unmethylated CpG-poor region. In order to 
determine if MBD2 has a unique region that gives it this function it should be compared to 
MBD3. MBD2 and MBD3 are similar in structure, but MBD3 does not bind to methylated DNA. 
Comparing the differences in the domains of these two could uncover a region that is not shared 
between the two and is responsible for how MBD2 binds CpG-poor DNA and represses the -
globin gene. This would also give researchers an idea of where to focus their efforts in trying to 
uncover how MBD2 is binding.  
Conclusion 
One of the main gaps each of these DNA binding proteins have in common is the 
mechanism by which they bind to and regulate the -globin gene. For each of the three DNA 
binding proteins there is debate as to how they repress transcription of the -globin gene. This 
shows that while much is known about how these factors work, there is still a lot to be 
uncovered. To help answer these question some experiments that could be done are to investigate 
how KLF1 binds the -globin gene in human cells and to compare the domains of MBD2 and 
MBD3 to elucidate if the differences account for what gives MBD2 the ability to bind to CpG-




above will hopefully provide some clarity as to how the -globin gene is being repressed by these 
transcription factors.  
Another gap these DNA binding proteins share is uncertainty about how they are 
interacting with each other to repress the -globin gene. There is evidence showing some of these 
transcription factors work together, but there is much left to be studied about how these 
interactions occur. Understanding how the transcription factors regulate and interact with each 
other would also provide more clarity about to how the -globin gene is being regulated, and 
would give a better idea of which transcription factors to target as a therapeutic treatment. It is 
possible that targeting factors that are not regulating each other would result in a greater increase 
in -globin gene expression than knockdown of either transcription factor alone. This idea will be 





Chapter 5: Simultaneous Targeting of Multiple -globin Repressors: 
Literature on Dual Knockdowns 
 
 
As discussed in Chapters 2 and 4, the transcription factors KLF1, BCL11A, and MBD2 
are repressors of -globin gene expression. It is well established that knockdown of any one of 
these genes results in a significant increase in -globin expression. This introduces the question 
of whether knockdown of more than one simultaneously would increase -globin expression 
more than a single knockdown. There has been limited investigation into this question. Some of 
these studies focus on the genes presented here, and some investigate combinations of 
knockdowns of other -globin repressors.  
In a 2013 study, a proteomic screen was done in MEL, and verified in K562 cells, to 
identify BCL11A-containing multiprotein complexes. The co-purified proteins were fractionated 
in SDS/PAGE, followed by liquid chromatography, and then subjected to tandem MS peptide 
sequencing. They then performed co-IP assays to confirm their result. Two of the BCL11A-
interacting proteins they identified are LSD1 and DNMT1. They first investigated the 
combinations of BCL11A and LSD1, and then BCL11A and DNMT1, in repressing -globin 
expression (248). LSD1 is the lysine-specific demethylase 1 and is a histone demethylase. Two 
models were used to measure changes in -globin expression. The EpoR-Cre system was used to 
create an erythroid-specific compound BCL11A homozygous – LSD1 heterozygous knockout in 
human YAC transgenic mice. Mice homozygous for LSD1 loss results in embryonic lethality 
due to severe anemia, so LSD1 heterozygotes were used. Using this system, they measured the 
mRNA concentrations via qRT-PCR in peripheral blood (PB) in 8-12 week-old mice. They saw 




increase, in BCL11A -/- compared to compound BCL11A -/- : LSD1 +/- mice. The BCL11A -/- 
was increased 383-fold from the WT YAC control mice, which express 0.02% -globin mRNA, 
and the compound BCL11A -/- : LSD1 +/- was increased 615-fold compared to the control mice. 
Both of these increases are statistically significant, with the compound -/- : +/- resulting in a 
statistically significant increase in -globin mRNA compared to the single knockdowns (Table 
1). Their second model used the hematopoietic selective and IFN inducible Mx1-Cre allele to 
generate complete loss of BCL11A and LSD1 (263) (264). They used this model to create 
BCL11A -/- : LSD1 -/- (dual knockout) mice. Again, mRNA concentrations were measured via 
qRT-PCR in PB of 8-12 week-old mice. They first showed the effect single knockouts of the 
genes had in comparison to WT-YAC control mice. LSD1 knockout resulted in no increase in 
-globin mRNA expression. BCL11A knockout resulted in a statistically significant increase in 
-globin mRNA to 12.9% – a 515-fold increase compared to control. The dual knockout resulted 
in a statistically significant increase of -globin mRNA to 18.2% – a 728-fold increase compared 
to control, a statistically significant 1.4-fold increase compared to BCL11A knockout, and a 
significant 455-fold increase compared to LSD1 knockout. The dual knockout using this model 
also resulted in a statistically significant increase in -globin mRNA compared to each of the 
single gene knockouts.  
The difference between these two models is that the EpoR-Cre system is erythroid 
specific while the Mx1-Cre system is not erythroid specific. Additionally, Mx1-Cre is an 
inducible system that acts during the adult stage while EpoR-Cre causes a homozygous deletion 
at the embryonic stage, which is what makes Epor-Cre lethal and Mx1-Cre not. The Mx1-Cre 
system allows for the creation of LSD1 null mice, but the EpoR-Cre system can only be used to 




: LSD1 +/- model resulted in a smaller increase in -globin mRNA compared to the BCL11A -/- : 
LSD1 -/- system, 615-fold compared to 728-fold. This is about a 1.2-fold difference between the 
two models. It is not stated if this is a significant difference between the two models. It seems 
that the two models work about the same in increasing -globin mRNA. These findings indicate 
knockout of BCL11A and LSD1 have an additive effect on increasing -globin mRNA, but 
targeting LSD1 is probably not a feasible treatment because the EpoR-Cre generated compound 
KO mice exhibited mild anemia as well as a decrease in white blood cells. Additionally, they 
discuss that LSD1-depleted CD34+ cells exhibit proerythroblast and basophilic erythroblast 
morphology – the mature polychromatophilic and orthochromatic erythroblast are absent at day 9 
of differentiation in culture. These findings indicate LSD1 is important for normal erythroid 
development and terminal differentiation.  
Xu et.al. also investigated the combination of DNMT1 and BCL11A (248). Another 
BCL11A-containing protein they identified is DNA methyltransferase 1 (DNMT1). DNMT1 is a 
DNA methyltransferase, so it adds methyl groups to DNA, which plays an important role in 
repressing globin gene expression. They found DNMT1 has enzymatic activity with BCL11A, so 
they decided to investigate its role in -globin expression. To investigate this, they used the 
EpoR-Cre system in human YAC transgenic mice to create erythroid specific 
BCL11A/DNMT1 double knockouts. They observed embryonic lethality with the DNMT1 
knockouts, so they used erythroid specific BCL11A -/-: DNMT1 +/- mice. They saw a 
statistically significant increase from 11.2% -globin mRNA in BCL11A -/- mice to 23.6% -
globin mRNA in BCL11A -/- : DNMT1 +/- – a 2.1-fold increase in expression (Table 1). Their 
results show BCL11A and DNMT1 also have an additive effect in increasing -globin mRNA 




targets because knockout of these genes impairs erythropoiesis and terminal differentiation (248) 
(265) (266), the results are still interesting because they show promise for using dual knockouts 
to increase -globin gene expression.  
Another study, performed in 2016, did double knockouts of BCL11A and LRF in 
HUDEP-2 cells using CRISPR/Cas9. First, they used HPLC to show single knockouts of 
BCL11A or LRF increase the ratio of HbF to HbA from about 2% in control cells to about 60% 
in each of the single knockouts. Then they show the double knockouts increase the ratio to about 
90% HbF, indicating the double knockout of the two genes has an additive effect on HbF 
expression (Table 1) (267). However, there are some issues with this paper. First, FACS of fetal 
liver cells from E14.5 LRF null mice indicates that disrupting LRF results in ineffective 
differentiation (268). This makes it impractical to use LRF as a target to increase HbF. This 
drawback makes it questionable how this study achieved these results with LRF knockouts. The 
study mentioned ineffective differentiation of CD34+ but not HUDEP-2 cells in which LRF is 
knocked out. CD34+ cells provide a more normal representation of human erythropoiesis than 
HUDEP-2 cells. Another issue with this paper is how they display their data. All of their data is 
depicted as the ratio of HbF – the percentage of -globin HbF to total globin HbF. They do not 
show any data on the levels of -globin or -globin expression alone; this makes it hard to know 
if the increased ratios are due to an increase in -globin or a decrease in -globin expression.  
One more study, performed in 2013, investigated the effect of dual knockout of BCL11A 
and KLF1 on -globin expression (154). This study used the mouse line PAC8.1, which carries a 
human -globin locus transgene. They crossed PAC8.1 mice carrying either a KLF1 KO allele or 
a floxed allele of BCL11A and used a knockin EpoR-Cre allele in order to create erythroid-




Chapter 2.2.b. They first studied how - and -globin expression changed in these mice at 
embryonic time points E14.5 and E18.5. They used fetal liver RNA to perform qRT-PCR and 
E18.5 blood samples to perform western blots. They saw a significant increase in -globin 
mRNA and HbF ratios in the KLF1 +/-, BCL11A -/-, and BCL11A -/- : KLF1 +/- mice when 
compared to PAC8.1 BCL11A floxed control mice. The largest increase was for the BCL11A -/- 
: KLF1 +/- mice and the smallest increase was in the KLF1 +/- mice. At both time points the 
BCL11A KO resulted in a statistically significant increase in the /(+) ratio compared to the 
KLF1 +/-, and the BCL11A -/- : KLF1 +/- resulted in a statistically significant increase in the 
/(+) ratio compared to the single knockouts (Table 1). They also studied the effect on -globin 
expression postnatally in young 4-5 week-old mice and adult >10 weeks old mice. They 
performed qRT-PCR from bone marrow RNA. They saw the same results as in the embryonic 
mice. The increase in -globin mRNA was reduced in adult compared to embryonic mice but still 
significant. This is not unexpected because it is difficult to reactivate the silenced -globin gene 
in mice. It is also worth noting that this study saw a smaller fold increase of -globin mRNA than 
in the other studies. An explanation for this could be because KLF1 and BCL11A are in the same 
pathway. KLF1 normally works to activate the role of BCL11A in repressing -globin 
expression, so knocking down or knocking out two genes that are in the same pathway could 







































































































































Table 1: Fold Changes in -globin Expression in Dual Knockdowns Previously Seen in 
the Literature 
Data from some of the dual knockdown/out experiments discussed above. An X indicates data was 




Chapter 6: Materials and Methods 
 
 
1. 293T Culture 
293T cells are cultured in T75 flasks at 37°C with 5% CO2 in Dulbecco’s Modified eagle 
Medium (DMEM). A 500 mL bottle of DMEM is made by adding of 10% fetal bovine serum 
(FBS), 1% of 100x Penicillin/Streptomycin (P/S), 5 mL of 1M HEPES buffer, 5 mL of 100x 
non-essential amino acids, and 5 mL of 200 mM L-alanyl-L-glutamine. When the cells reach 
approximately 70% confluency they are split. To split the cells the DMEM media was vacuumed 
off and the attached cells are washed with 5 mL of PBS. The PBS is vacuumed off and then 2 
mL of 0.05% trypsin is added to the cells to detach them. The flask with the trypsin is placed in 
the incubator for 1 minute until the cells start to detach. Then 7 mL of DMEM complete media + 
P/S is added to the flask and all of the media is transferred to a centrifuge tube. The tube is 
centrifuged in an Eppendorf Centrifuge 5810 R (15 amp version) at 800 rpm for 5 minutes. After 
centrifuging, the supernatant is vacuumed off and the cell pellet is resuspended with 1 mL of 
DMEM complete media +P/S. Then the cells are either split between 3 T75 flasks at volumes of 
20 mL each or a fraction of the cell pellet is seeded in one T75 flask at a volume of 20 mL and a 
density of 4 x 106; the rest of the cells are discarded.  
2. Lentivirus Packaging 
293T cells are seeded at 4.5 x 106 cells per 10 cm dish (typically 10 dishes per desired 
virus). The dishes are placed in the incubator at 37°C with 5% CO2 overnight to allow the cells to 
attach. The next day the attached cells are used to package the lentivirus. A mixture is made for 




or shSCR): 250 µL opti-MEM, the volume of desired virus plasmid to have 8 µg, the volume of 
psPAX2 to have 6 µg, pMD2.G to have 4 µg. psPAX2 is the packaging vector, which is an 
empty lentiviral backbone used to package the cDNA into virus. pMD2.G is envelope vector that 
coats the virus. A separate mixture of 196 µL of opti-MEM and 54 µL of PEI (1 g/L) is made 
and then added to the mixture with the plasmids. PEI is polyethylenimine. It is responsible for 
condensing DNA into positively charged particles that allow for the DNA:PEI complex to be 
more easily endocytosed by the cells and the DNA released into the cytoplasm (269). The 
mixture is incubated at room temperature. The media on the plates is changed to 5 mL of DMEM 
complete media with 10% FBS and with no P/S. After 8-10 minutes of incubation, 500 µL of the 
mixture is pipetted drop by drop in a spiral pattern onto the plates. The plates are placed at 3% 
CO2 overnight. The next morning the cells are checked for GFP using the Olympus Ix70 
fluorescent microscope at 200x magnification and the media is changed to 5 mL DMEM 
complete media with 5% FBS and 1% P/S. Then the dishes are placed at 10% CO2. On the third 
day this media is collected by pipetting it off and transferring into a 50 mL tube. 5 mL of new 
DMEM complete media with 5% FBS is pipetted onto the dishes. The tube of collected virus is 
centrifuged at 3,000 g at 4°C for 5 minutes. The supernatant containing the virus is poured into a 
50 mL tube and stored at 4°C. The following day, the fourth day, the supernatant collection 
process is repeated and then the culture dishes are discarded.  
3. Ultracentrifugation to Concentrate Virus 
The 30 mL of supernatant collected from lentivirus packaging is filtered using a 0.45 µM 
PES filter, a 10 mL syringe, 21G x 1.5 (0.8 mm x 40mm) gauge needles, and ultracentrifuge 
tubes are. A 10 mL syringe is used to obtain the virus supernatant. Then the syringe is attached 




membrane and into the ultracentrifuge tube. This process is repeated until all of the virus is 
filtered. A needle is used when the virus volume gets low and the syringe cannot reach the 
bottom of the tube; the needle can be attached to the syringe to reach to the bottom. The 
ultracentrifuge tubes are balanced and parafilm is used to seal them. A Beckman Coulter Optima 
L-80 XP Ultracentrifuge with the SW32Ti rotor to centrifuge the samples at 4°C at 28,000 rpm 
for 90 minutes. The buckets are then removed and opened in the hood to remove the 
ultracentrifuge tubes. The parafilm is removed and the supernatant is vacuumed off. Then, the 
pellet containing the virus is resuspended in 400 µL of SFEM II complete media – P/S. The 
tubes containing the virus are then covered with parafilm and placed at 4°C overnight. The 
following day the media is collected from the ultracentrifuge tubes and transferred to 1.5 mL 
centrifuge tubes. The tubes are centrifuged at maximum speed at 4°C for 15 minutes to get rid of 
any sediment. Then, the supernatant containing virus is transferred to a 1.5 mL centrifuge tube in 
100 µL aliquots. The aliquots are stored at -80°C. The titer of the frozen aliquots is reduced by 
approximately 50% compared to fresh virus.  
4. HUDEP-2 Cell Culture 
HUDEP-2 cells are grown at a density of 2.5 x 105 per T25 flask. The media used is 
SFEM II. Complete media is made by taking 45 mL aliquots and adding 45 L each of DOX (1 
g/mL) and EPO (3 IU/mL), 22.5 L of SCF (100 g/mL), 9 L of DEX (10−6M), and 450 L 
of L-alanyl-L-glutamine (200 mM). 5 mL of media is used on the first day of passage. Two days 
later, 2 more mL of media are added to the flasks. On the third day the cells are split by 
collecting the media in a 15 mL centrifuge tube and centrifuging at 300 g for 5 minutes. After 
centrifuging the media is vacuumed off and the pellet is resuspended in 1 mL of SFEM II 




SFEM II complete media to achieve the density of 2.5 x 105cells per flask. Cells are incubated at 
37°C at 5% CO2. 
5. Creation of BCL11A Vector 
All viral vectors used in this thesis were in the pRRL expression vector. The MBD2 
shRNA vector was gifted from the Ginder lab. The map of the shMBD2 vector is in Figure 10. 
The shBCL11A vector was created by using the Broad Institute’s website to search for human 
BCL11A sequences. One of the oligo sequences, oligo 1 or S1, was selected from a study that 
had designed it and had shown success using it for knockdowns (246). The map for the 
shBCL11A vector can be found in Figure 11. Four were selected to design four different pairs of 
oligos (Tables 2 and 3). The forward and reverse oligos for each pair were designed and ordered 
to be synthesized using IDT. Once the oligos arrived they were centrifuged at 12,000g for 1 
minute to make sure all of the powder was at the bottom of the tube. Then the samples were 
reconstituted in water to bring their concentration to 100 M. Next, the forward and reverse 
oligos were phosphorylated and annealed. To do this 1 L of the forward oligo, 1 L of the 
reverse oligo, 1 L of 10x T4 ligation buffer, 6.5 L Hyclone H2O, and 0.5 L of T4 PNK (10 
L total) were combined in a tube. This was done for each of the four sets of oligos. To anneal 
the oligos, they were incubated in the Bio Rad C1000 Touch Thermal Cycler with the following 
parameters: 37°C for 30 minutes, 95°C for 5 minutes, and then ramp down to 25°C at 5°C/min. 
An annealed a diluted stock was made: 1 L of the annealed primers was added to 199 L 
hyclone water to make a 1:200 dilution. Next, the plasmid the oligos were to be inserted into had 




The shBCL11A oligos were cloned into the vector containing shMBD2. This shMBD2 
plasmid was double digested with XhoI and MluI, with recognition sites located on either side of 
the shMBD2, to remove the shMBD2. All enzymes were obtained from Thermo Scientific and 1 
L of enzyme can digest 1 g of plasmid DNA in 5 minutes. Single digests with one restriction 
enzyme were performed to ensure the restriction enzymes were cutting. A 50 L digestion was 
performed for the double digest and 20 L digests were used for the single digestions. To 
perform the double digest a mixture was made containing: 2.5 g of shMBD2 plasmid, 5 L of 
FD (10x) green buffer, 2.5 L MluI restriction enzyme, 2.5 L XhoI restriction enzyme, and 
H2O to 50 L. For the single digests a mixture was made containing: 1.0 g of shMBD2 
plasmid, 2 L of FD (10x) green buffer, either 1.0 L MluI restriction enzyme or 1.0 L XhoI 
restriction enzyme, and H2O to 20 L. The restriction digests were sealed with parafilm and 
incubated in a water bath at 37°C for at least 2 hours. The reaction was terminated by placing the 
tubes on a heat block at 80°C for 5 minutes. Then the products were separated on a 0.7% agarose 
gel. The samples were loaded into respective lanes on the agarose gel and then run at 130V for 
30 minutes. A UV light was used to visualize the bands. The double digested band was excised 
and placed in a 1.5 mL centrifuge tube that had previously been weighed. DNA purification was 
performed to obtain the vector that no longer contains shMBD2, using the Omega E.Z.N.A Gel 
Extraction Kit.  
The annealed oligos were then ligated into the plasmids. A mixture was prepared 
containing 50 ng double digested plasmid, 1 L diluted oligo, 5 L 2x quick ligase buffer, 1 L 
Quick Ligase, and hyclone H2O to 11 L. A mixture was made for each oligo, as well as one that 
contains water in place of the oligo as a negative control. The mixtures were incubated at room 




Transformation into Stbl3 competent cells: 11 L of each sample was pipetted into 
respective tubes containing 50 L of Stbl3 and pipetted up and down to mix. The mixtures were 
incubated on ice for 30 minutes. During this time agar plates were taken out of the fridge and 
placed at room temperature to warm up. Agar plates are made with LB media containing 
ampicillin (100 g/mL) for colony selection. The samples were then heat shocked at 42°C for 45 
seconds, and then placed on ice for 2 minutes. Next, the mouth of the bottle containing SOC 
media was passed through a flame to sterilize it, then 200 L of SOC media was pipetted into 
each sample. The tubes were then placed in the shaking incubator at 32°C at 180 rpm for 90 
minutes. The tubes were retrieved from the incubator and 200 L of each sample was pipetted 
onto its respective agar plate and 6-8 glass beads are added to each plate. The plates were shaken 
horizontally by hand for 10 minutes and then placed in an incubator at 32°C for 10 minutes. The 
plates were retrieved from the incubator and the glass beads were removed. The plates were 
placed back in the incubator, upside down, at 32°C overnight. The next day the plates were 
checked to confirm that no or very few colonies grew on the negative control plate compared to 
the plates containing samples. If the negative control plate had growth it would indicate the 
plasmid was not digested and the growth seen on the plates containing samples likely does not 
contain the product with the oligos ligated in. A pipette tip was used to select 4 single colonies. 
Then the pipette tip was dropped into a test tube containing 3 mL of LB broth. Additional 
colonies from each sample were selected to spread on fresh agar plates. The plates were 
incubated at 32°C overnight and the tubes were capped and placed in the shaking incubator at 
220 rpm at 32°C overnight. The next day the plasmid purification is performed on each sample 
using the Omega E.Z.N.A Plasmid DNA Mini Kit II. The product obtained is nanodropped using 




260/230 measurements two plasmid preparations with the best measurements – highest 
concentration, 1.9 – 2.1 for 260/280, and 2.0 – 2.4 for 260/230 – from each set of oligos were 
selected to send to Eurofins Genomics for sequencing. When the sequencing results were 
obtained, they were copied into NCBI Blast global align tool along with the designed oligo 
sequences to check that the plasmid products were what we expected them to be. All sequences 
were fully aligned, indicating they were complete and contained our intended oligos.  
Once it was confirmed that the oligos contained the intended shBCL11A, they were used 
to package lentivirus following the protocol above. The lentivirus was not concentrated; fresh 
virus was used to infect 293T cells to the test efficiency of the shBCL11A plasmids. 8 x 105 
293T cells were seeded per well in a 6 well plate with DMEM complete media – P/S one day 
before infection. To infect the cells the media was vacuumed off and 2 mL of virus was pipetted 
onto the cells as well as 4 L of 4 g/L polybrene and then placed at 37°C at 5% CO2 for 7 
hours. Then the media was vacuumed off and replaced with 2 mL of DMEM complete media + 
P/S. After 3 days, the 293T cells were collected by scraping them off of the plate and then 
centrifuged at 800 rpm. The cells were then used to extract RNA and make cDNA to run a qRT-
PCR following the protocol below. The knockdown efficiency of each shRNA was measured. 
shRNA #1 (S1) was selected to be used for BCL11A knockdown experiments because it gave 
the best knockdown efficiency, about 70%, of the 4 shRNAs tested. This was the shRNA 
previously designed by another group (246). We used shBCL11A S1 to perform the experiments 






shBCL11A Oligo Target 
Oligo 1 ACAGAACACTCATGGATTAAG 
Oligo 2 ACCTCTCCATGGGATTCATAT 
Oligo 3 GCCAACCTAATTACCTGTATT 
Oligo 4 GCATAGACGATGGCACTGTTA 
 
 
Oligo Name Forward Oligo Reverse Oligo 
Set 1 5 – CGCGTCCCCACAGAACACTCATGGATTAAG 
TCAAGAGCTTAATCCATGAGTGTTCTGTTTTTTGG
AAC – 3  
 
5 – TCGAGTTCCAAAAAACAGAACACTCATGGA 
TTAAGCTCTTGACTTAATCCATGAGTGTTCTGTGG
GGA – 3 
 
Set 2 5 – CGCGTCCCCACCTCTCCATGGGATTCATAT 
TCAAGAGATATGAATCCCATGGAGAGGTTTTTTG
GAAC – 3 
 
5 – TCGAGTTCCAAAAAACCTCTCCATGGGATTC 
ATATCTCTTGAATATGAATCCCATGGAGAGGTGG
GGA – 3 
 
Set 3 5 – CGCGTCCCCGCCAACCTAATTACCTGTATT 
TCAAGAGAATACAGGTAATTAGGTTGGCTTTTTGG
AAC – 3 
 
5 – TCGAGTTCCAAAAAGCCAACCTAATTACCT 
GTATTCTCTTGAAATACAGGTAATTAGGTTGGCGG
GGA – 3 
 
Set 4 5 – CGCGTCCCCGCATAGACGATGGCACTGTTA 
TCAAGAGTAACAGTGCCATCGTCTATGCTTTTTGG
AAC – 3 
 
5 – TCGAGTTCCAAAAAGCATAGACGATGGCAC 
TGTTACTCTTGATAACAGTGCCATCGTCTATGCGG




6. Creation of the M/B Dual Viral Vector containing both the MBD2 and BCL11A 
shRNAs 
To create the dual vector, the shBCL11A was amplified from its PRRL vector and ligated 
into the PRRL vector already containing shMBD2. The map for the shM/B dual vector is in 
Figure 12. The site for inserting shBCL11A was chosen directly 3’ to shMBD2, between the 
Table 2: BCL11A Target Sequences 
These are the sequences selected from the Broad Institute website to be used to design oligos.  
Table 3: shBCL11A Oligo Sequences 
These are the oligo sequences designed and ordered from IDT. Red = MluI restriction enzyme 





XhoI and EcoRV restriction sites. Primers were designed to target the H1 promoter and the 
shBCL11A of the shBCL11A vector. The forward primer was designed to have an XhoI site on 
the 5’ end so that the product can be ligated into the cut plasmid. The reverse primer was 
designed to have a one base pair mismatch to XhoI so that the final product would not have two 
XhoI restriction sites as it would cause problems during digestion. The primer sequences are 
found in Table 4. The primers were used to amplify the region of interest from the shBCL11A 
PRRL vector. The Q5 Hot Start High-Fidelity 2x Master Mix protocol was followed: 12.5 L Q5 
high fidelity 2x master mix, 10 M forward primer, 10 M reverse primer, 0.1 ng shBCL11A 
PRRL plasmid, and DEPC H2O to 25 L. The mix was briefly vortexed and centrifuged. Then it 
was placed in the Bio Rad C1000 Touch Thermal Cycler using the following parameters: Initial 
denaturation: 98°C for 30 seconds; 35 cycles of: 98°C for 10 seconds, 65°C for 20 seconds, and 
72°C for 10 seconds; the final extension step is 72°C for 2 minutes. The product was then run on 
a 2% agarose gel at 90V for 50 minutes. The product size is 308 bp. The resulting band was cut 
out of the gel and purified using the Omega E.Z.N.A gel extraction kit.  
Next, a double digest of the shMBD2 PRRL vector was performed. The same protocol 
was followed as described in the section for designing the shBCL11A vector, except the 
restriction enzymes XhoI and EcoRV were used in this digest. The restriction enzymes were also 
used for digestion one at a time because they are located close to each other in the plasmid; 2.5 
L of EcoRV was added first and the mixture was incubated at 37°C for 2 hours. After 2 hours 
the XhoI enzyme was added and the mixture was incubated at 37°C for another 2 hours. The 
sample was gel purified following the protocol described above. The purified shBCL11A was 




described above. Then, the sample was cleaned up using the Monarch PCR and DNA cleanup 
kit.  
The BCL11A PCR and shMBD2 plasmid digested products were then ligated together. A 
mixture was made with 2 L T4 10x ligation buffer, 50 ng of the shMBD2 PRRL double 
digested vector, 5.94 ng of the shBCL11A PCR insert (this concentration was determined using 
the online NEBiocalculator tool), 1 L T4 ligase, 2 L 10 mM ATP, and DI H2O to 20 L. This 
was incubated at room temperature for 1 hour and then was transformed into Stbl3 cells 
following the protocol outlined in the previous section. The protocols for streaking agar plates 
and inoculating LB broth and the plasmid preparations were also followed. The sequencing 
showed both of the shRNAs were present in the final product, so virus packaging and 
transfections were performed following the protocol laid out above. 
Forward Primer 5’ – CGTATATTCTCGAGTTCGAACGCTGACGTCATC – 3’  
Reverse Primer 5’ – GGAATTCGATATCAAGCTTCTCGcGTTCCAAAAAAC – 3’ 
 
 
7. Lentiviral Infection 
2 x 105 HUDEP-2 cells are plated per well of a 12 well plate. The number HUDEP-2 
cells needed is determined, then they are centrifuged 300 g for 5 minutes. The supernatant is 
vacuumed off and the pellet is resuspended with 1 mL of SFEM II complete media – P/S. Then 
the remaining volume of SFEM II complete media – P/S needed to pipette 600 L of cells at a 
density of 2 x 105 into the desired number of wells of the 12 well plates is added to the 
Table 4: Primers Targeting the shBCL11A 
These are the primers sequences designed and ordered from IDT. Red = XhoI restriction enzyme 
sequence. Blue = EcoRV. Green = shBCL11A. Yellow = H1 promoter. The reverse primer was 
designed to have a one base pair mismatch (the small c) so that the final product would not have two 




resuspended cell pellet. Next, 100 L of appropriate virus from frozen stock is pipetted into 
well(s) to achieve a dilution of 1:20. If using fresh virus the volume used would be 50 L of 
virus to achieve the 1:20 dilution, but because frozen virus is used 100 L of virus has to be used 
to achieve the same dilution to account for the approximately 50% loss of virus due to being 
frozen. The total volume of each well of the 12 well plate should be 1 mL, so 300 L of SFEM II 
complete media – P/S is added to make up the remaining volume of the well. The plate is sealed 
and centrifuged in an Eppendorf Centrifuge 5810 R (15 amp version) at 2,800 rpm at 32°C for 
90 minutes. After centrifuging the plate is incubated at 37°C and 5% CO2 for 3 hours. Then 1.5 
mL of SFEM II complete media – P/S is added to each well and then the plate is placed in the 
incubator. The following day the cells are resuspended using a bulb pipette and transferred into 
labeled 15 mL centrifuge tubes. The tubes are centrifuged at 300 g for 5 minutes, and the 
supernatants are vacuumed off. Then, each pellet is resuspended with 1 mL of SFEM II complete 
media + P/S and transferred into its respective well in a 6-well plate. Then 1 mL more of SFEM 
II complete media + P/S is added to each well, bringing the total volume to 2 mL and the plates 
are placed in the incubator. After 72 hours the cells are checked for GFP using the Olympus Ix70 
fluorescent microscope at 200x magnification and 2 mL more of SFEM II complete media + P/S 
is added to each well of cells. The following day each sample is transferred into a T25 flask and 
SFEM II complete media + P/S media is added to bring the volume of each flask to 5 mL. The 
following day 2 mL more of media is added to each flask. 5 days after infection the cells are 
collected to be differentiated. For quality control, every time an infection is done 2 wells are 
infected with SCR lentivirus and 1 well is also prepared as an uninfected control. The SCR 
control is what the results are compared to, but the uninfected control is included to make sure no 




plasmid contains a GFP element, so GFP is used to assess the efficiency of infection. At least 
80% GFP expressing cells indicates the infection worked well. If there is GFP in the uninfected 
control well it indicates there was a contamination and the experiment needs to be thrown. The 
uninfected control is also used for qRT-PCR to compare the SCR results to make sure the SCR 
lentivirus did not knock down any of the genes or affect - and -globin gene expression.  
8. Cell Differentiation 
1 million cells are differentiated per well of a 6-well plate. Cell number is counted for 
each sample and it is determined how many wells will need to be differentiated per sample, i.e. if 
the cell number for sample X is 5.6 x 106 then 6 wells will be used to differentiate this sample. 
Per well, 3 mL of differentiation media will be needed; 2 mL when initially plating the cells and 
1 mL more 2 days later. When differentiating the cells, Iscove Modified Dulbecco Media 
(IMDM) media is used. To make the media, P/S is added to IMDM to 2% of the volume. The 
volume of IMDM + P/S needed for the differentiation experiment is calculated. Then Human AB 
serum is added to 5% of the volume. The IMDM plus Human AB serum media is filtered using a 
0.45 µm PES filter. Once the media is filtered DOX (1 g/mL), EPO (3 IU/mL), Insulin (10 
g/mL), Heparin (3 U/mL), 100x Holo-Transferrin (500 g/mL), and 1x L-alanyl-L-glutamine 
(200 mM) is added to the media. The cell pellets are resuspended in full media to have 1 x 106 
cells per 2 mL of media for each well, i.e. if sample X needs to be differentiated in 6 wells then 
the cell pellet will be resuspended in 6 mL of IMDM media. 1 mL of cells are plated in 6 well 
plates and then 1 mL more of IMDM is added to each well to bring the total volume per well to 2 
mL. Then the plate(s) are placed in the incubator at 37°C with 5% CO2. Two days later 1 mL of 
differentiation media is added to each well. Exactly 72 hours after differentiation is initiated the 




supernatant is vacuumed off, the cell pellet is resuspended with 5 mL of PBS, and centrifuged 
again at 1,500 rpm. Finally, the supernatant is carefully removed and then the cell pellet is stored 
at -80°C. 
9. RNA Extraction 
Cell pellets are resuspended in 750 µL of Trizol and incubated at room temperature for 5 
minutes. Then, 200 µL of Chloroform is added to each sample, they are vortexed for 15 seconds, 
and incubated at room temperature for 15 minutes. The samples are centrifuged in an Eppendorf 
Centrifuge 5424 R at 12,000 g at 4°C for 15 minutes. The upper, clear aqueous phase is 
transferred to a new tube, taking care not to transfer any of the lower, pink layer. Then, 5 µL of 
glycogen (final 5 mg/mL) is pipetted into each sample. Next, an equal volume of 2-proponol is 
added to each sample. The samples are inverted 6-8 times (do not shake) and placed at -20°C 
overnight. The samples are centrifuged at 12,000 g at 4°C for 15 minutes, and the supernatant is 
discarded, leaving the RNA pellet. The pellet is washed with 1 mL of chilled 70% RNA ethanol 
and then centrifuged at 7,500 g at 4°C for 5 minutes. The supernatant is removed and the tube 
with pellet is put on ice and left to dry. The pellet is resuspended in 10 µL of DEPC water. The 
NanoDrop ND-1000 Spectrophotometer is used to determine the purity and concentration of the 
resuspended RNA pellet. 
10. cDNA Preparation 
A 20 µL reaction is used to make the cDNA, where 1 µL is Oligo dT (0.5 g/l), 4 µL is 
5x Reaction Buffer, 0.5 µL is RiboLock RNase inhibitor (40 U/L), 2 µL is dTNP mix (10 mM), 
1 µL is RevertAid M-MuLV Reverse Transcriptase (200 U/l), and the remaining 11.5 µL is 




of mRNA in the reaction is 100 ng/µL. Once the samples are prepared, they are loaded into Bio 
Rad C1000 Touch Thermal Cycler set to incubate at 42°C for 60 minutes and then terminate the 
reaction by heating to 70°C for 10 minutes. As a quality control one of the samples is used for an 
additional reaction where no RevertAid M-MuLV Reverse Transcriptase is added. cDNA 
samples are stored at -20°C.  
11. qRT-PCR Protocol 
A 20 µL reaction is prepared with 10 µL of Quantabio PerfeCta MultiPlex qPCR 
ToughMix Low ROX mix, 1 µL of Thermo Fisher predesigned TaqMan probe (human - globin, 
human -globin, hMBD2, hBCL11A, or hPPIA), 8 µL of DEPC water, and 1 µL of cDNA 
(equal to 100 ng of RNA). The Thermo Fisher TaqMan probes are predesigned assays that 
contain the TaqMan probe and the PCR primer set specific for the product to be amplified. 
TaqMan works by annealing probes that contain a fluorophore to the sample and then when the 
Taq Polymerase synthesizes a new strand it cleaves the probe resulting in the release of 
florescence that is measured by the instrument. A master mix is made with the qPCR ToughMix, 
TaqMan probe, and DEPC water. 19 µL of the master mix is pipetted into the corresponding 
wells in the 96 well plate. Then 1 µL of cDNA is pipetted into respective wells. Each sample is 
run in triplicate in a 96 well plate. The plate is then sealed and wrapped in foil to protect it from 
light exposure while it is transported to the instrument. The foil wrapped plate is briefly vortexed 
and then spun down. The plate is then loaded into the QuantStudio 3 applied biosystems 
instrument by Thermo Fisher Scientific. The ΔΔCT method is used to calculate relative amounts 
of RNA and the running parameters used were 95°C for 3 minutes for initial denaturation, 95°C 
for 15 seconds and then 60°C for 1 minute. The last two steps are repeated 40 times. On every 




L of DEPC water is added instead of cDNA. This is done to check that none of the reagents 
used in the experiment were contaminated and there should be no amplification for this well. The 
other quality control is to include one well that uses 1 L of the cDNA sample prepared without 
Reverse Transcriptase. This well should also not be amplified and checks that none of the 
reagents used to make cDNA were contaminated and that genomic DNA is not being amplified. 
If amplification is seen in either of these wells then it indicates there is an issue with the water or 
reagents and the results cannot be used. 
12. Statistical Analysis 
One-way ANOVA with a Tukey-test for all pairwise comparisons was run using 






Figure 10: shMBD2 Map 
The mapping for the PRRL vector containing the shMBD2. The location of the shRNA is indicated 
by the pink highlighting. The XhoI, MluI, and EcoRV restriction sites can be seen on either side of 
the pink highlighting. The H1 promoter is identified by the white arrow directly before the pink 
highlighting. The region that provides GFP is indicated by the bright green arrow. The region that 
provides ampicillin resistance is indicated by the mint arrow. This plasmid and mapping was gifted 







Figure 11: shBCL11A Map 
The mapping for the PRRL vector containing the shBCL11A. The location of the shRNA is indicated 
by the pink highlighting. The XhoI and EcoRV restriction sites can be seen on either side of the pink 
highlighting. The H1 promoter is identified by the white arrow directly before the pink highlighting. 
The region that provides GFP is indicated by the bright green arrow. The region that provides 







Figure 12: shMBD2/shBCL11A Dual Expression Vector Map 
The mapping for the PRRL vector containing the shMBD2 and shBCL11A. The location of the 
shRNAs is indicated by the pink highlighting. The H1 promoter is identified by the white arrow 
directly before the pink highlighting. The region that provides GFP is indicated by the bright green 









As discussed in Chapter 5, there is good evidence that targeting two different genes that 
repress the -globin gene is a feasible method for increasing -globin mRNA expression more 
than single knockdowns. This thesis proposes to perform a study where BCL11A and MBD2 are 
knocked down simultaneously. These genes were chosen because they are the most commonly 
studied; there is good evidence single knockdowns or knockouts of these genes gives a 
significant increase in -globin mRNA expression (153) (168) (171) (246) (247) (248). This 
thesis proposes performing knockdown of the genes rather than knockout. There are several 
reasons for this. One is that knockout could increase -globin expression so much that it would 
not allow us to detect an additive effect of the knockdown of a second gene. Another is that it is 
not feasible to knockout an entire gene in patients as there could be deleterious effects. We 
propose using the HUDEP-2 cell system because it portrays adult erythropoiesis. When HUDEP-
2 cells are differentiated they express mostly -globin. This is a useful model because it mimics 
human adult erythroid cells that have very little expression of -globin. After performing the 
experiments in HUDEP-2 cells, the results should be verified using erythroid-differentiated 
CD34+ cells. We think the dual knockdown combination will work better than the single 
knockdowns at increasing -globin mRNA expression. This thesis will present preliminary data 
to support our hypothesis that dual knockdowns increase -globin mRNA expression more than 
single knockdowns due to an additive effect. Our goal is the data presented here will encourage 




findings provide better insight about combining repressor genes to target as a therapeutic 
approach. 
Results 
First, the four oligos designed to target BCL11A were tested for their knockdown 
efficiency. Lentivirus was made for each of the four BCL11A shRNAs following the protocol 
described in Chapter 6. To check knockdown efficiency of the shRNAs, 293T cells were infected 
with the lentivirus. The results showed that shRNA #1 (S1) knocked down BCL11A by about 
60% and shRNA #3 (S3) knocked down BCL11A by about 30% compared to the scramble 
(SCR) control shRNA. shRNAs #2 and #4 resulted in no knockdown of BCL11A compared to 
the SCR control (Figure 13). S1 and S3 lentivirus was then used to infect HUDEP-2 cells to 
verify the findings seen in 293T cells. S1 lentivirus resulted in about 60% knockdown of 
BCL11A compared to SCR, but S3 lentivirus showed very little knockdown of BCL11A in 
HUDEP-2 (Figure 14). From these results, the S1 shRNA was chosen for future experiments.  
Single, dual, or SCR control expression vectors were used to package lentivirus in 293T 
cells, which was then used to infect HUDEP-2 cells. The single vectors are targeting either 
BCL11A or the MBD2; the dual vector contains both shRNAs and targets BCL11A and MBD2 
simultaneously. From this point forward it will be referred to as the M/B dual vector; the control 
vector is a scrambled sequence. Three days after infection the HUDEP-2 cells were checked for 
GFP. GFP is used to assess the efficiency of infection because the lentiviral plasmid contains the 
GFP element. Only infections that resulted in GFP in ≥ 80% of cells were used to continue the 
experiments. A representative microscope image for GFP expression is in Figure 15 and 




Five days after infection the cells were differentiated for three days to become more 
erythroid, and RNA was prepared for qRT-PCR. Refer to methods in Chapter 7 for more detailed 
explanations. The qRT-PCR results show 80% knockdown of BCL11A with the single viral 
construct and 70% knockdown of BCL11A mRNA with the dual viral construct compared to 
SCR, which are statistically significant knockdowns of BCL11A mRNA (Figure 16A). The 
results for MBD2 with the single viral construct show 90% knockdown and 70% knockdown for 
the dual viral construct compared to SCR, which are also statistically significant knockdowns of 
MBD2 mRNA (Figure 16B). All three of the viral constructs significantly increase -globin 
mRNA compared to the SCR control, with the M/B dual knockdown having higher expression 
than single knockdowns (Figure 17A, black lines). The knockdown of BCL11A alone results in a 
mean 22-fold increase of -globin mRNA and the knockdown of MBD2 alone results in a 17.5-
fold increase in -globin mRNA; there is no statistically significant difference between these two 
knockdowns. The M/B dual knockdown results in a 45-fold increase in -globin mRNA. This is a 
statistically significant increase compared to each of the single knockdowns (Figure 17A, red 
lines). Cells for all three of the viral constructs exhibit significantly increased -globin mRNA 
by about 1.4-fold compared to control, but there is no significant difference in -globin mRNA 
between the three viral constructs (Figure 17B). The increase in -globin is not as large as the 
increase in -globin mRNA expression.  
The /(+)% for all three of the knockdowns is significantly increased compared to 
control, as seen in Figure 17C. The mean baseline for /(+)% for SCR is 0.21%. Knockdown 
of BCL11A alone results in a statistically significant increase to 3.2%, a 14.7-fold increase. 
Knockdown of MBD2 alone results in a statistically significant increase to 2.9%, a 14-fold 




fold increase. There is no significant difference for /(+)% between the BCL11A and MBD2 
single knockdowns (Figure 17C, black lines), but there are statistically significant differences in 
the dual knockdown compared to each of the singles (Figure 17C, red lines). The difference 
between the BCL11A single and the M/B dual knockdown is a 2.1-fold increase. The difference 
between the MBD2 single and the M/B dual knockdown is a 2.3-fold increase. These findings 
show that simultaneous knockdown of BCL11A and MBD2 increases -globin mRNA more than 
single knockdowns, and that M/B dual knockdown has an additive effect on increasing -globin 
mRNA expression. The action of the M/B dual knockdown is additive rather than synergistic 
because the effect it has on increasing -globin mRNA and the /(+)% is approximately the 
same as the effect of the single knockdowns if their results were combined. If the action was 
synergistic the increase in -globin mRNA and the /(+)% caused by the M/B dual knockdown 
would be much larger than the effect caused by the single knockdowns. 
 
 
Figure 13: Knockdown Efficiency of the Four BCL11A shRNAs in 293T Cells 
qRT-PCR data showing how each shRNA worked at knocking down BCL11A in 293T cells. SCR = 
scramble control, S1 = shRNA #1, S2 = shRNA #2, S3 = shRNA #3, and S4 = shRNA #4. n = 2. 







Figure 14: Knockdown Efficiency of S1 and S3 BCL11A shRNAs in HUDEP-2 Cells 
qRT-PCR data showing efficiency of BCL11A S1 and BCL11A S3 shRNA knockdown of BCL11A 
mRNA. SCR is set to 1. SCR = scramble control, S1 = shRNA #1 and S3 = shRNA #3. n = 3. 
HUDEP-2 cells were infected for 5 days before collected for qRT-PCR. 
Figure 15: Microscope Images of Lentiviral Infected Cells 
HUDEP-2 cells infected with shMBD2 lentivirus. Left: brightfield image to show how many cells are 
in the field. Right: The same field of cells showing fluorescent cells with GFP to test infection 




Trial # Virus Number of cells 
in brightfield 




1 SCR 264 214 81.1  
BCL11A 173 171 98.8  
MBD2 200 200 100  
M/B dual 282 274 97.2 
2 SCR 370 360 97.3  
BCL11A 127 121 95.3  
MBD2 132 132 100  
M/B dual 243 202 83.1 
3 SCR 200 200 100  
BCL11A 141 131 92.91  
MBD2 136 132 97.0  
M/B dual 178 155 87.1 
4 SCR 109 103 94.4  
BCL11A 111 111 100  
MBD2 140 138 98.6  
M/B dual 129 122 94.6 
 
 
Table 5: Cell Counts for Lentiviral Infected Cells used in this Study 
Hand counts of each sample of infected cells under brightfield or green fluorescent light. The 
shBCL11A used was the S1 construct. M/B dual = the shMBD2 & shBCL11A dual vector. These 






Figure 16: Knockdown of BCL11A and MBD2 
qRT-PCR data. Panels A-B are compared to the SCR control set to 1. A: Knockdown of BCL11A 
using the shBCL11A exclusive lentiviral vector or the M/B dual lentiviral vector. B: Knockdown of 
MBD2 using the shMBD2 exclusive lentiviral vector or the M/B dual lentiviral vector. Sample size of 
4. Statistical test: one-way ANOVA with Tukey correction. Black lines are statistical comparisons to 
SCR. Red lines are statistical comparisons to the M/B dual results. Cells were infected for 5 days then 








The data presented here is evidence that dual knockdown of MBD2 and BCL11A 
increases -globin mRNA significantly more than either of the single knockdowns. Comparing 
our results to the literature, studies measuring the effects of knockdown of BCL11A in CD34+ 
cells report 97% - 99% knockdown, where we saw 80% knockdown. These studies report a 3 to 
Figure 17: - and -globin Expression in HUDEP-2 Cells with MBD2 and BCL11A 
Knockdown 
qRT-PCR data. Panels A-B are compared to the SCR control set to 1. Panel C is compared to SCR 
which is a percentage. A: -globin gene expression for each of the single knockdowns and the dual 
knockdown. B: -globin gene expression for each of the single knockdowns and the dual knockdown. 
C: Total globin ratios (/(+)%) for each of the single knockdowns and the dual knockdown. Sample 
size of 4. Statistical test: one-way ANOVA with Tukey correction. Black lines are statistical 
comparisons to SCR. Red lines are statistical comparisons to the M/B dual results. Cells were 
infected for 5 days then differentiated for 3 days before collected for qRT-PCR. Significance p < 




6.5 fold increase in -globin mRNA, with the average being a 4.2-fold increase (153) (246) (247) 
(248). A study measuring the effects of BCL11A knockout in HUDEP-2 cells saw a 30-fold 
increase in -globin mRNA (267). Our knockdown of BCL11A showed a 22-fold increase in -
globin mRNA. Our increase in -globin mRNA is larger than what the studies in CD34+ cells 
saw, but similar to the study done in HUDEP-2 cells. The differences between results in 
HUDEP-2 compared to CD34+ cells suggest that in a clinical setting -globin mRNA increases 
may be smaller than in HUDEP-2 cells. One study reported the change in -globin mRNA in 
CD34+ cells with BCL11A knocked down 99% to have a 1.5-fold increase (248). Our findings 
for how BCL11A influences -globin mRNA agree with what has been shown in the literature; 
we saw a 1.4-fold increase in mRNA.  
A study of how MBD2 knockdown affects -globin mRNA in CD34+ cells showed it 
results in a 5-fold increase as a result of 90% knockdown of MBD2 (171). Another study in 
HUDEP-2 cells saw 98% knockdown of MBD2 results in about a 10-fold increase in /+ ratio 
compared to control. This study also saw knockout of MBD2 in HUDEP-2 cells resulted in at 
least a 300-fold increase in -globin mRNA, no significant change in -globin mRNA, and a 
/+ of about 50% (168). We saw 90% knockdown of MBD2 with a resulting 17.5-fold 
increase -globin mRNA and a 14-fold increase in the /+ ratio. Our findings agree with the 
experiments done in HUDEP-2 cells; the increase in the /+ ratio is similar. Again, the more 
clinically relevant CD34+ cells appear to show less increase in -globin, further emphasizing the 
probable need for double knockdown. Additionally, the one study that looked at -globin mRNA 




To our knowledge, this is the first study to explore single knockdowns of BCL11A and 
MBD2 at the same time in the same cell system. This allows us to compare the results for each 
gene to see if knockdown of one works better than knockdown of the other. We show our 
shRNAs knockdown these genes by about the same amount, 80 – 90%, and both significantly 
increase -globin mRNA compared to the SCR control. However, there is no significant 
difference in the amount of the increase seen in -globin mRNA, 22-fold for BCL11A vs. 17.5-
fold for MBD2. There are no significant differences in the /+ ratio with the two different 
knockdowns either. Knockdown of BCL11A resulted in a 15-fold increase and knockdown of 
MBD2 resulted in a 14-fold increase, 3.2% vs. 2.9%. These findings show that knockdown of 
BCL11A or MBD2 significantly increases the amount of -globin mRNA by about the same 
amount and that there is not one gene that is better to target than the other with regard to 
increasing -globin expression. Our findings could mean BCL11A and MBD2 are not working in 
the same pathway, because there is a significant difference in the increase in -globin mRNA in 
the single knockdowns compared to the dual knockdown. In contrast, our results could be due to 
the dual knockdown depleting the interactions of BCL11A and MBD2 with the NuRD complex 
to a greater extent than single knockdown of either gene. The greater depletion of the NuRD 
complex would result in less silencing of the -globin gene and a larger increase in -globin 
mRNA even if BCL11A and MBD2 are in the same pathway.   
Our findings present strong evidence that it would be promising to investigate 
combinations of the other DNA binding proteins discussed in this thesis – combinations of KLF1 
and MBD2, and KLF1 and BCL11A. Investigating each of these combinations will hopefully 
determine which of the three combinations is the most effective at increasing -globin gene 




therapeutic treatment for individuals with -hemoglobinopathies. Future directions this thesis 
proposes are to perform studies where the different combinations of knockdowns of these DNA 
binding proteins are tested. These three genes are of interest because they are the most 
commonly studied; there is good evidence single knockdowns or knockouts of these genes gives 
a significant increase in -globin gene expression (153) (168) (171) (246) (247) (248). We also 
propose that each of the dual knockouts should be done in the same system. The studies 
described in Chapters 5 and 6 were done in various different model systems. Some were 
performed in YAC transgenic mice, some in CD34+ cells, and some in HUDEP-2 cells. We 
believe that in order to compare how well each of the dual knockouts works they all need to be 
done in the same system. We hypothesize there will be one dual knockout combination that 
works better than the others at increasing -globin gene expression. We also hypothesize the 
combination of BCL11A and KLF1 will be the least effective combination because of the role 
KLF1 has in regulating the BCL11A gene, that is, they are in the same pathway. We think this 
combination should still be tested, however. In conclusion, we present strong evidence that dual 
knockdown of BCL11A and MBD2 simultaneously works significantly better at increasing -
globin mRNA than single knockdown of either gene. Western blots need to be done to confirm 
the knockdown of BCL11A and MBD2, the decrease in -globin mRNA, and the increase in -
globin mRNA at the protein level. To have a more quantitative measure for - and -globin 
expression, HPLC could be performed. We use this evidence to support future studies on dual 
knockdowns of other DNA binding proteins to determine which combination would be the best 





Chapter 8: Conclusions 
 
 
Erythropoiesis is the synthesis of RBCs, which are essential for transporting oxygen 
throughout the body. RBCs are created in two phases during development. The first of these is 
primitive erythropoiesis, which is responsible for the creation of embryonic hemoglobin (1). 
Then there is a switch from primitive to definitive erythropoiesis, which correlates with 
expression of the - and -globin genes (4). The switches in globin gene expression are referred 
to as hemoglobin switching, and in most humans the - to -globin switch is completed by 
approximately 6 months of life (24) (25). In some humans this switch never or incompletely 
occurs, resulting in a condition called HPFH. Individuals with this condition have elevated levels 
of HbF compared to normal (49). The occurrence of a -hemoglobinopathy and a HPFH variant 
in an individual can ameliorate their symptoms (50). This led researchers to seek ways to 
manipulate genes in order to increase HbF to treat patients with -hemoglobinopathies. The two 
-hemoglobinopathies most often focused on for this treatment are SCD and -thalassemia, as 
they affect millions of people worldwide (68) (85). Both disorders have treatments available, but 
patients still have morbidity and early death compared to healthy individuals (89). The only cure 
available is BMT but this treatment can cause GVHD which can lead to death (96). The lack of a 
safe treatment method available to all patients highlights the need to develop a treatment that 
increases HbF. The strategies being worked on to achieve this will be discussed in this chapter. 
In this thesis, the focus on increasing HbF has been on three DNA binding proteins 
implicated in regulating -globin expression: KLF1, BCL11A, and MBD2. KLF1 is an erythroid 




(123) (124). In fact, it is crucial for transcription of the -globin gene, because knockouts of 
KLF1 in mouse models have shown it is embryonic lethal due to the subsequent development of 
-thalassemia (123) (135). BCL11A is a transcription factor that regulates genes in many 
different processes, one of those being repression of the -globin gene (64) (144). BCL11A 
represses the -globin gene because when it is knocked out in mouse models this results in an 
increase in HbF, without embryonic lethality (147) (146). Subsequent studies led to the 
incidental finding that KLF1 regulates BCL11A; when KLF1 is knocked down the level of 
BCL11A is also reduced (153) (154). This indicates that KLF1 indirectly negatively regulates -
globin gene expression by promoting the expression of BCL11A to repress the -globin gene. 
MBD2 is a DNA binding protein that represses -globin gene transcription through its 
recruitment of the NuRD complex (161). NuRD is a complex of proteins that provide histone 
deacetylase and chromatin remodeling activities that allow MBD2 to repress transcription (163) 
(164). MBD2 was also verified to regulate the -globin gene through knockouts in mouse and 
cell models (165) (166) (167).  
Although investigation of these DNA binding proteins progresses, there are still gaps in 
knowledge. The gaps discussed in this thesis for KLF1 include the function of KLF1 at the -
globin gene in human fetal erythroid cells and how the type and location of KLF1 mutations 
affect the severity of the condition the mutation causes. There is evidence that KLF1 binds the -
globin gene promoter during fetal development, but the majority of the studies on this topic have 
been performed in YAC transgenic mice (124) (128) (228) (229) (230) (231). We propose there 
could be differences in the timing of KLF1 function depending on the model system used. In an 




expresses HbF or HbA, like the HUDEP-1 and HUDEP-2 cell lines (194). When analyzing 
numerous mutations of KLF1 that cause various disorders we found the majority of the 
mutations occur in the zinc fingers. It is not surprising that variants in the zinc fingers cause an 
increase in HbF because they facilitate binding of KLF1 to the DNA. I propose that these 
variants could be causing KLF1 to change the specificity of its target sites. I also propose that 
more sequencing needs to be done to compare KLF1 mutations that do not cause a phenotype to 
mutations that do to see if there are critical regions in the KLF1 gene. Understanding the critical 
regions of the gene that cause disease or HPFH would provide researchers with the knowledge of 
where in the gene they should target for treatment of the -hemoglobinopathies.   
The gaps presented in this thesis for BCL11A are the methods by which it binds to the -
globin gene in order to repress it and what other proteins or complexes it is interacting with. 
There was uncertainty about where BCL11A binds in the -globin locus to repress the -globin 
gene. Previous theories suggested it acts at a distance to the gene promoters (246) (247), but 
convincing more recent evidence shows it binds to a sequence at the -115 distal motif of the -
globin promoter (155) (254). Researchers are still unsure about the exact mechanism by which 
BCL11A functions to repress the -globin gene.  The current theory is that BCL11A is binding at 
the -115 promoter site as well as at the distal sites in the -globin locus in order to repress the -
globin gene. There are many reported interactions of BCL11A with other proteins,  for example 
its interactions with-  RbAp48/46 and CHD4 of the NuRD complex (157) (246). The 
understanding of if/how BCL11A is interacting with the NuRD complex is still unclear. The 





This is the predominant gap in knowledge for MBD2. It is known MBD2 represses the -
globin gene, but there are no methylated CpG islands within the -globin gene for which MBD2 
can bind to (165) – its normal mechanism of action (162) (167). MBD2 is binding to CpG-poor 
DNA somehow, but it is not known how. We propose the differences between MBD2 and 
MBD3 should be studied to determine if regions not shared by the two account for the ability of 
MBD2 to bind to CpG-poor DNA. 
We focused on the gap that knockdown of combinations of the KLF1, BCL11A, and 
MBD2 DNA binding proteins could be more effective at increasing -globin than single 
knockdowns. We propose knocking down all three possible combinations of two of the three 
factors simultaneously. We presented previous studies that have done dual knockdowns to 
increase -globin expression, to show what is available in the literature (154) (248) (267). We 
want to test combinations of these three genes because they are the most studied. We performed 
single and dual knockdown of BCL11A and MBD2 and show the dual knockdown results in a 
significantly greater increase in -globin gene expression and /(+)% than either of the single 
knockdowns. These findings indicate dual knockdowns have an additive effect on increasing 
HbF and would likely be a more effective treatment for -hemoglobinopathies than single 
knockdowns. We use these results to support our hypothesis that the other combinations of genes 
should be tested to determine which combination would be the best target for a treatment. 
Using shRNAs that target these genes is one viable option for a treatment and has been 
shown to be possible in clinical trials testing gene therapy of BCL11A (149) (151). While this is 
an option it is not the best solution for large scale distribution. Gene therapy would not be easily 




available in third world countries where a large proportion of -hemoglobinopathy cases occur. 
A better treatment that could be developed is to create small molecule inhibitors that could be 
taken orally. Potential targets of a small molecule inhibitor for KLF1 and BCL11A could be their 
zinc fingers. They are what allow these proteins to bind DNA; by preventing this function they 
would no longer be able to promote -globin or repress -globin expression. Targeting the KLF1 
zinc fingers is a strong candidate as demonstrated by the cases of increased HbF as a result of 
missense variants in the KLF1 zinc fingers, discussed in Chapter 4.1.c. Small molecule inhibitors 
could also be used to target the interaction of KLF1 with p300 and CBP. KLF1 needs these 
interactions to transcriptionally activate the -globin gene, so blocking these interactions would 
repress the expression of -globin. For MBD2, studies have shown its IDR or coiled-coil domain 
would be promising targets for a small molecule inhibitor (170) (171) (168). Gene therapy and 
small molecule inhibitors are both promising treatment options being considered for -
hemoglobinopathies. While clinical trials to develop gene therapy that targets BCL11A are 
underway, more data needs to be collected on how this treatment is working before it can be 
decided if it is a better treatment option than what is currently available. Research needs to be 
done to create small molecule inhibitors that target these regions as this is the more feasible 
treatment option in order to reach the largest number of people. As previously mentioned, small 
molecule inhibitors would be a better treatment option than gene therapy as the majority of 
individuals with -hemoglobinopathies are located in underdeveloped nations where access to 
the technology for gene editing is scarce. It will take time to develop these treatment methods, 
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